WO2022098808A1 - Therapeutic agents for treating hepatocellular carcinoma - Google Patents
Therapeutic agents for treating hepatocellular carcinoma Download PDFInfo
- Publication number
- WO2022098808A1 WO2022098808A1 PCT/US2021/057970 US2021057970W WO2022098808A1 WO 2022098808 A1 WO2022098808 A1 WO 2022098808A1 US 2021057970 W US2021057970 W US 2021057970W WO 2022098808 A1 WO2022098808 A1 WO 2022098808A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- independently
- hetaryl
- alkylnr
- aryl
- Prior art date
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 title claims abstract description 84
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title claims abstract description 82
- 239000003814 drug Substances 0.000 title claims description 17
- 229940124597 therapeutic agent Drugs 0.000 title claims description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 96
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 75
- 238000011282 treatment Methods 0.000 claims abstract description 74
- 238000000034 method Methods 0.000 claims abstract description 66
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- 239000013078 crystal Substances 0.000 claims abstract description 27
- 239000000651 prodrug Substances 0.000 claims abstract description 27
- 229940002612 prodrug Drugs 0.000 claims abstract description 27
- 239000012453 solvate Substances 0.000 claims abstract description 27
- 150000004677 hydrates Chemical class 0.000 claims abstract description 19
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 325
- 125000001072 heteroaryl group Chemical group 0.000 claims description 96
- 125000003118 aryl group Chemical group 0.000 claims description 86
- 201000007270 liver cancer Diseases 0.000 claims description 72
- 229910052760 oxygen Inorganic materials 0.000 claims description 65
- 229910052717 sulfur Inorganic materials 0.000 claims description 65
- 125000004429 atom Chemical group 0.000 claims description 63
- -1 C1-4alkyl cycloalkyl Chemical group 0.000 claims description 43
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 39
- 229910052736 halogen Inorganic materials 0.000 claims description 36
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 36
- 150000002367 halogens Chemical class 0.000 claims description 34
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 21
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 12
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 201000003076 Angiosarcoma Diseases 0.000 claims description 5
- 206010004593 Bile duct cancer Diseases 0.000 claims description 5
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 5
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 3
- 238000009097 single-agent therapy Methods 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 11
- 238000009472 formulation Methods 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 description 78
- 241001465754 Metazoa Species 0.000 description 73
- 101710183564 Pyridoxal 5'-phosphate synthase subunit PdxT Proteins 0.000 description 33
- 239000003981 vehicle Substances 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 28
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 26
- 102100035459 Pyruvate dehydrogenase protein X component, mitochondrial Human genes 0.000 description 26
- 230000037396 body weight Effects 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 20
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 19
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 19
- 229960003787 sorafenib Drugs 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 210000003494 hepatocyte Anatomy 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 12
- 230000004614 tumor growth Effects 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 208000019425 cirrhosis of liver Diseases 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 9
- 206010016654 Fibrosis Diseases 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 8
- 239000005089 Luciferase Substances 0.000 description 8
- 230000007882 cirrhosis Effects 0.000 description 8
- 230000003442 weekly effect Effects 0.000 description 8
- 102000029749 Microtubule Human genes 0.000 description 7
- 108091022875 Microtubule Proteins 0.000 description 7
- 210000004688 microtubule Anatomy 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 231100000682 maximum tolerated dose Toxicity 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 241000283984 Rodentia Species 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 229940125961 compound 24 Drugs 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 206010011906 Death Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 3
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000011887 Necropsy Methods 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000004579 body weight change Effects 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000000368 destabilizing effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MTJHLONVHHPNSI-IBGZPJMESA-N 1-ethyl-3-[2-methoxy-4-[5-methyl-4-[[(1S)-1-(3-pyridinyl)butyl]amino]-2-pyrimidinyl]phenyl]urea Chemical compound N([C@@H](CCC)C=1C=NC=CC=1)C(C(=CN=1)C)=NC=1C1=CC=C(NC(=O)NCC)C(OC)=C1 MTJHLONVHHPNSI-IBGZPJMESA-N 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 241000021375 Xenogenes Species 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000006880 cross-coupling reaction Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000007674 radiofrequency ablation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002723 toxicity assay Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- LNJZJDLDXQQJSG-UHFFFAOYSA-N 2-phenylpyrazine Chemical class C1=CC=CC=C1C1=CN=CC=N1 LNJZJDLDXQQJSG-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000698776 Duma Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 238000005577 Kumada cross-coupling reaction Methods 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 238000006411 Negishi coupling reaction Methods 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000003833 Wallach reaction Methods 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000005911 anti-cytotoxic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002257 antimetastatic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003101 antineoplastic hormone agonist and antagonist Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000010109 chemoembolization Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000002050 international nonproprietary name Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- VVNXEADCOVSAER-UHFFFAOYSA-N lithium sodium Chemical compound [Li].[Na] VVNXEADCOVSAER-UHFFFAOYSA-N 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- AZVARJHZBXHUSO-DZQVEHCYSA-N methyl (1R,4R,12S)-4-methyl-3,7-dioxo-10-(5,6,7-trimethoxy-1H-indole-2-carbonyl)-5,10-diazatetracyclo[7.4.0.01,12.02,6]trideca-2(6),8-diene-4-carboxylate Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)N[C@@](C5=O)(C)C(=O)OC)=CC2=C1 AZVARJHZBXHUSO-DZQVEHCYSA-N 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- KXCAEQNNTZANTK-UHFFFAOYSA-N stannane Chemical class [SnH4] KXCAEQNNTZANTK-UHFFFAOYSA-N 0.000 description 1
- 210000004722 stifle Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009790 vascular invasion Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- HCC Hepatocellular carcinoma
- HCC liver cirrhosis
- hepatitis B or C hepatitis B or C
- cirrhosis cirrhosis
- HCC is now the third leading cause of cancer deaths worldwide, with over 500,000 people affected (Global Data - HEPATOCELLULAR CARCINOMA – OPPORTUNITY ANALYSIS AND FORECASTS TO 2024, pg.21).
- the incidence of HCC is highest in Asia and Africa, where the endemic high prevalence of hepatitis B and hepatitis C strongly predisposes to the development of chronic liver disease and subsequent development of HCC.
- Each year in the United States approximately 15,000 men and 6,000 women are diagnosed with primary liver cancer.
- HCC hepatitis C virus
- NASH nonalcoholic fatty liver disease
- NASH nonalcoholic steatohepatitis
- the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (I): or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: R 1 is H, C 1-4 alkyl; Q is a bond, or C 1-4 alkyl; A is aryl, heteroaryl optionally substituted with 0-3 substituents independently chosen from halogen, C 1-4 alkyl, CH 2 F, CHF 2 , CF 3 , CN, aryl, hetaryl, OCF 3 , OC 1-4 alkyl, OC 2- 5 alkylNR 4 R 5 , O-aryl, O-hetaryl, CO2R4, CONR 4 R 5 , nitro, NR 4 R 5 , C 1-4 alkylNR 4 R 5 , NR 6 C 1-4 alkylNR 4 R 5 , NR
- R 1 is H, C 1-4 alkyl
- Q is a bond, or C 1-4 alkyl
- W is selected from H, C 1-4 alkyl, C 2-6 alkenyl; where C 1-4 alkyl or C 2-6 alkenyl may be optionally substituted with C 1-4 alkyl, OH, OC 1-4 alkyl, NR 15 R 16 ; R 15 , and R 16 are each independently H, C 1-4 alkyl, C 1-4 alkyl cycloalkyl, C 1-4 alkyl cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR 17 R 17 is selected from H, C 1-4 alkyl; and wherein when Y is CH 2 R 12 then R 12 is not H, C 1-2 alkyl.
- the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (III): or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: X 1 , X 2 , X 3 , X 4 are selected from the following: (i) X 1 and X 2 are N and X 3 and X 4 are C independently substituted with Y; (ii) X 1 and X 4 are N and X 2 and X 3 are C independently substituted with Y; (iii) X 1 and X 3 are N and X 2 and X 4 are C independently substituted with Y; (iv) X 2 and X 4 are N and X 1 and X 3 are C independently substituted with Y; (v) X 1 is N and X 2 , X 3 , and X 4 are C independently substituted with Y; (vi)
- the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (IV): or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: X 1 , X 2 , X 3 , X 4 are selected from the following: (i) X 1 and X 2 are N and X 3 and X 4 are C independently substituted with Y; (ii) X 1 and X 4 are N and X 2 and X 3 are C independently substituted with Y; (iii) X 1 and X 3 are N and X 2 and X 4 are C independently substituted with Y; (iv) X 2 and X 4 are N and X 1 and X 3 are C independently substituted with Y; (v) X 1 is N and X 2 , X 3 , and X 4 are C independently substituted with Y; (vi)
- the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (V): or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: X 1 , X 2 , X 3 , X 4 are selected from the following: (i) X 1 and X 2 are N and X 3 and X 4 are C independently substituted with Y; (ii) X 1 and X 4 are N and X 2 and X 3 are C independently substituted with Y; (iii) X 2 and X 4 are N and X 1 and X 3 are C independently substituted with Y; (iv) X 1 is N and X 2 , X 3 , and X 4 are C independently substituted with Y; (v) X 3 is N and X 1 , X 2 , and X 4 are C independently substituted with Y; (v) X 3
- the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (VI): or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: R’1 is C 1-4 alkyl, R’ 2 is independently selected from the group consisting of: OH, NHCOR’ 12 , and NHCONHR’12; R’12 is independently selected from the group consisting of H, C 1-4 alkyl optionally substituted with OH, OC 1-4 alkyl or NR’ 15 R’ 16 ; R’ 15 and R’ 16 are each independently selected from H and C 1-4 alkyl; X’ 1 , X’ 2 , X’ 3 , X’ 4 are selected from the following: (i) X’ 1 and X’ 2 are N and X’ 3 and X’ 4 are C independently substituted with Y’; (ii) X’ 1 and
- the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment a compound having the structure: or a pharmaceutically acceptable prodrug, salt, hydrate, solvate, or crystal form thereof.
- the method can treat a liver cancer that is selected from the group consisting of hepatocellular carcinoma (HCC), fibrolamellar HCC, bile duct cancer, angiosarcoma, and secondary liver cancer.
- the method may treat HCC.
- the subject may be a mammal that has a liver cancer.
- the subject is a human who has liver cancer.
- the methods can further comprise monitoring the subject for a change in a sign and/or a symptom of liver cancer that is responsive to administering the compound.
- the methods of treatment may be administered as a monotherapy.
- the methods of treatment may be administered as part of a combination therapy and can further comprise one or more additional therapeutic interventions.
- the methods of treatment may further comprise surgery.
- the methods of treatment may further comprise administration of at least one additional anti-cancer agent.
- the compound can be administered intravenously, subcutaneously, or orally.
- the disclosure provides for the use of the compounds disclosed herein, or a pharmaceutically acceptable prodrug, salt, hydrate, solvate, or crystal form thereof, for the treatment of a liver cancer.
- the disclosure provides for the use of the compounds disclosed herein, or a pharmaceutically acceptable prodrug, salt, hydrate, solvate, or crystal form thereof, for the preparation of a medicament for the treatment of a liver cancer.
- the use can be for the treatment of a liver cancer selected from the group consisting of: hepatocellular carcinoma (HCC), fibrolamellar HCC, bile duct cancer, angiosarcoma, and secondary liver cancer.
- the liver cancer is HCC.
- Figures 1A-1E depict viability for individual HCC cell lines HepG2 ( Figure 1A); Hep3B (Figure 1B); Hep40 (Figure 1C); Huh7 ( Figure 1D); and PLC5 ( Figure 1E) as a function of candidate compound concentration.
- Figure 2 depicts IC50 summary information for candidate compounds in HCC cell lines and primary human hepatocytes.
- Figure 3 depicts the maximum tolerated dose survival curve for TXR-311 in BALB/c mice.
- Figure 4 depicts body weight changes in maximum tolerated dose assays for different concentrations of TXR-311.
- Figure 5 depicts body weight changes in the PDX1 cohort for animals treated with TXR-311 relative to vehicle.
- Figure 6 depicts tumor measurement in the PDX1 cohort for animals treated with TXR-311 relative to vehicle.
- Figure 7 depicts tumor images (IVIS) for animals in the PDX1 cohort that were treated with vehicle.
- Figure 8 depicts tumor images (IVIS) for animals in the PDX1 cohort that were treated with TXR-311.
- Figure 9 depicts differences in tumor size on Day 25 for animals in the PDX1 cohort for animals treated with TXR-311 relative to vehicle.
- Figure 10 depicts the difference in tumor volume in the PDX1 cohort for animals treated with TXR-311 relative to vehicle.
- Figure 11 depicts the body weight in the PDX2 cohort for animals treated with TXR- 311 or sorafenib relative to vehicle.
- Figure 12 depicts the IVIS-derived tumor measurement in the PDX2 cohort for animals treated with TXR-311 or sorafenib relative to vehicle.
- Figure 13 depicts tumor images (IVIS) for animals in the PDX2 cohort that were treated with vehicle, TXR-311, or sorafenib at Day 0.
- IVIS tumor images
- Figure 14 depicts tumor images (IVIS) for animals in the PDX2 cohort that were treated with vehicle, TXR-311, or sorafenib at Day 7.
- Figure 15 depicts tumor images (IVIS) for animals in the PDX2 cohort that were treated with vehicle, TXR-311, or sorafenib at Day 14.
- Figure 16 depicts tumor images (IVIS) for animals in the PDX2 cohort that were treated with vehicle, TXR-311, or sorafenib at Day 21.
- Figure 17 depicts tumor images (IVIS) for animals in the PDX2 cohort that were treated with vehicle, TXR-311, or sorafenib at Day 28.
- Figure 18 depicts tumor images (IVIS) for animals in the PDX2 cohort that were treated with vehicle, TXR-311, or sorafenib at Day 35.
- Figure 19 depicts tumor images (IVIS) for animals in the PDX2 cohort that were treated with vehicle, TXR-311, or sorafenib at Day 42.
- Figure 20 depicts tumor images (IVIS) summarizing tumor growth for animals in the PDX2 cohort that were treated with vehicle.
- Figure 21 depicts tumor images (IVIS) summarizing tumor growth for animals in the PDX2 cohort that were treated with TXR-311.
- Figure 22 depicts tumor images (IVIS) summarizing tumor growth for animals in the PDX2 cohort that were treated with sorafenib.
- Figure 23 depicts differences in tumor size for animals in the PDX2 cohort that were treated with vehicle, TXR-311, or sorafenib.
- Figure 24 depicts a graphical summary of the tumor volume data for animals in the PDX2 cohort that were treated with vehicle, TXR-311, or sorafenib.
- the disclosure provides methods that are directed to the treatment of liver cancer that comprise administration of compounds and compositions that are identified through a process that combines an initial computational-based analysis of approved or investigational drugs using DUMA, a proprietary artificial intelligence platform, and reviewing existing information available for candidate compounds along with performing additional research and development of the identified candidate compounds specifically directed to determine the efficacy of the compounds in the treatment of liver cancer.
- Using this type of evaluation provides several advantages relative to conventional therapeutic agent discovery, including reduction in the overall cost and time of providing new treatments and therapies for particular diseases and conditions.
- the initial screening of candidate compounds that have existing human safety and pharmacodynamic data provides a reduced risk of expensive failures late in development due to safety concerns.
- the disclosure provides methods of treating liver cancer, including hepatocellular carcinoma (HCC), comprising administering to a subject in need of treatment certain 2-phenyl pyrazines that have been previously described as microtubule inhibitors, and that have now, for the first time, been shown to be effective in the treatment of liver cancer.
- HCC hepatocellular carcinoma
- Microtubule binding agents include a broad range of structurally diverse compounds that can function to stabilize or destabilize the microtubule structure and assembly.
- stabilizing and destabilizing agents are used as clinically relevant anti-cancer drugs including stabilizing agents such as docetaxel, paclitaxel, and ixabepilone, and destabilizing agents such as the alkaloids, vincristine, vindesine, and vinblastine.
- Microtubule binding agents that destabilize microtubule structure are usually classified based on the domain to which they bind, either the vinca-domain or the colchicine binding site (or “CBS”). Some agents that bind the vinca-domain (e.g., vincristine, vindesine, and vinblastine) have been developed as therapeutics against specific types of cancers (e.g., breast, ovarian).
- tissue refers to an aggregate of multiple cells and/or cell products.
- the “gene” refers to a nucleic acid sequence or portion thereof that encodes a protein. Nucleic acid sequences may include, but are not limited to, DNA in any form, such as genomic DNA, cDNA, synthesized DNA. Nucleic acid sequences may also include RNA and RNA transcripts corresponding to DNA.
- the terms “peptide,” “polypeptide” and “protein” refer interchangeably to a molecule comprised of amino acid residues covalently linked by peptide bonds. A protein or peptide may contain at least three amino acids, and no limitation may be placed on the maximum number of amino acids that can comprise a protein or peptide sequence.
- Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types. “Polypeptides” include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others.
- polypeptides include natural peptides, recombinant peptides, synthetic peptides, or a combination thereof.
- patient and “subject” are used interchangeably to refer to animals that may be in need of a therapy that comprises the methods and compositions described herein.
- Non-limiting examples of animals that may be a patient or subject include animals such as primates (e.g., humans, and non-human primates, such chimpanzees, gorillas), and other mammals (e.g., cats, dogs, agricultural mammals, such as equines, bovines, ovines, porcines, horses, pigs, cows, sheep, laboratory rodents/animal model systems, such as hamsters, mice and rats, and rabbits).
- primates e.g., humans, and non-human primates, such chimpanzees, gorillas
- other mammals e.g., cats, dogs, agricultural mammals, such as equines, bovines, ovines, porcines, horses, pigs, cows, sheep, laboratory rodents/animal model systems, such as hamsters, mice and rats, and rabbits.
- a subject at risk of a condition includes subjects who by virtue of a known characteristic, such as a genetic marker, biomarker, existing disease or condition, or family history, are at a measurably or significantly higher risk (p ⁇ 0.05) relative to a control population of individuals not known to have such genetic marker, biomarker or family history or the like, of developing the condition.
- Certain risk factors may be associated with occurrence and/or onset of liver cancer, and may be used to identify subject who may be at risk of developing liver cancer, or who may be screened for liver cancer prior to onset of any symptoms (i.e., clinical conditions) associated with liver cancer.
- Non-limiting examples of risk factors include hepatitis B or hepatitis C infections, cirrhosis of the liver caused by alcoholism, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH).
- Disease or “clinical conditions” refer to a physiological state of an organism with an abnormal biological state. Abnormal biological states include, but are not limited to, an interruption, cessation or disorder of cells, tissues, body functions, systems or organs that may be inherent, inherited, caused by an infection (e.g., sepsis), caused by abnormal cell function, caused by abnormal cell division (e.g., cancer), and the like. As discussed in the aspects and embodiments herein, the methods relate to the treatment of liver cancer.
- liver cancer can refer broadly to any abnormal cell growth, neoplasm, or tumor in the liver.
- liver cancer relates to a malignant tumor or neoplasm and may include the non-limiting examples of hepatocellular carcinoma (HCC, or hepatoma), fibrolamellar HCC, cholangiocarcinoma (bile duct cancer), angiosarcoma (hemangiocarcinoma), and secondary liver cancer (metastasis to the liver, often (but not required to be) originating from colon or colorectal cancer).
- HCC hepatocellular carcinoma
- cholangiocarcinoma bile duct cancer
- angiosarcoma hemangiocarcinoma
- secondary liver cancer metalastasis to the liver, often (but not required to be) originating from colon or colorectal cancer.
- the liver cancer is HCC.
- the liver cancer is a secondary liver cancer.
- compositions refer to an agent that does not interfere with the effectiveness of the biological activity of an active ingredient, and which may be approved by a regulatory agency of the Federal government or a state government, or is listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly for use in humans. Accordingly, suitable pharmaceutically acceptable carriers include agents that do not interfere with the effectiveness of a pharmaceutical composition.
- pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable, preferably nontoxic, acids and bases, including inorganic and organic acids and bases, including but not limited to, sulfuric, citric, maleic, acetic, oxalic, hydrochloride, hydro bromide, hydro iodide, nitrate, sulfate, bisulfite, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, fornate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i)
- Pharmaceutically acceptable salts include those formed with free amino groups such as, but not limited to, those derived from hydrochloric, phosphoric, acetic, oxalic, and tartaric acids. Pharmaceutically acceptable salts also include those formed with free carboxyl groups such as, but not limited to, those derived from sodium, potassium, ammonium, sodium lithium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, and procaine.
- therapeutic agents refers to any drug, agent, biologically active agent, biological substance, chemical substance or biochemical substance that is capable of being administered in a therapeutically effective amount to a subject.
- therapeutic agents can include one or more compounds disclosed herein.
- terapéuticaally effective amount refers to an amount of a therapeutic agent, compound, formulation, material, or composition, as described herein effective to achieve a particular biological result. Such results may include, but are not limited to, the inhibition of a disease as determined by any means suitable in the art.
- An effective regime refers to a combination of an amount, frequency of administration and route of administration effective to treat a condition. Effective treatment delays onset of, reduces, inhibits deterioration of, or ameliorates at least one sign or symptom of the condition.
- a regime can be considered effective by demonstrating a statistically significant delay, reduction, inhibition, or amelioration (p ⁇ 0.05) in a sign or symptom comparing a population of treated human subjects (or animal models) having or at risk of the condition being treated relative to a control population of subjects (or animal models) with the condition who are not treated with the agent.
- the control population can be contemporaneously treated with a placebo or can be a historical control.
- a treatment can alternatively or additionally be considered effective if it reduces or ameliorates at least one sign or symptom of the condition in a treated subject relative to the same subject before treatment.
- the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (I): or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: R 1 is H, or C 1-4 alkyl; Q is a bond, or C 1-4 alkyl; A is aryl, heteroaryl optionally substituted with 0-3 substituents independently chosen from halogen, C 1-4 alkyl, CH 2 F, CHF 2 , CF 3 , CN, aryl, hetaryl, OCF 3 , OC 1-4 alkyl, OC 2- 5 alkylNR 4 R 5 , Oaryl, Ohetaryl, CO2R4, CONR 4 R 5 , nitro, NR 4 R 5 , C 1-4 alkylNR 4 R 5 , NR 6 C 1 - R 4 , R 5 are each independently H
- R 1 is H, C 1-4 alkyl
- Q is a bond, or C 1-4 alkyl
- A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C 1-4 alkyl, CH 2 F, CHF 2 , CF 3 , CN, aryl, hetaryl, OCF 3 , OC 1-4 alkyl, OC 2- 5 alkylNR 4 R 5 , Oaryl, Ohetaryl, CO2R4, CONR 4 R 5 , nitro, NR 4 R 5 , C 1-4 alkylN R4R 5 , NR 6 C 1-4 alkylN R 4 R 5 , NR 4 COR
- the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (III): or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: X 1 , X 2 , X 3 , X 4 are selected from the following: (i) X 1 and X 2 are N and X 3 and X 4 are C independently substituted with Y; (ii) X 1 and X 4 are N and X 2 and X 3 are C independently substituted with Y; (iii) X 1 and X 3 are N and X 2 and X 4 are C independently substituted with Y; (iv) X 2 and X 4 are N and X 1 and X 3 are C independently substituted with Y; (v) X 1 is N and X 2 , X 3 , and X 4 are C independently substituted with Y; (vi)
- the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (IV): or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: X 1 , X 2 , X 3 , X 4 are selected from the following: (i) X 1 and X 2 are N and X 3 and X 4 are C independently substituted with Y; (ii) X 1 and X 4 are N and X 2 and X 3 are C independently substituted with Y; (iii) X 1 and X 3 are N and X 2 and X 4 are C independently substituted with Y; (iv) X 2 and X 4 are N and X 1 and X 3 are C independently substituted with Y; (v) X 1 is N and X 2 , X 3 , and X 4 are C independently substituted with Y; (vi)
- the disclosure provides a method of treating HCC comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (V): or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: X 1 , X 2 , X 3 , X 4 are selected from the following: (i) X 1 and X 2 are N and X 3 and X 4 are C independently substituted with Y; (ii) X 1 and X 4 are N and X 2 and X 3 are C independently substituted with Y; (iii) X 2 and X 4 are N and X 1 and X 3 are C independently substituted with Y; (iv) X 1 is N and X 2 , X 3 , and X 4 are C independently substituted with Y; (v) X 3 is N and X 1 , X 2 , and X 4 are C independently substituted with Y; (v) X 3
- R’1 is C 1-4 alkyl
- R’2 is independently selected from the group consisting of: OH, NHCOR’12, and NHCONHR’ 12
- R’12 is independently selected from the group consisting of H, C 1-4 alkyl optionally substituted with OH, OC 1-4 alkyl or NR’15R’16
- R’ 15 and R’ 16 are each independently selected from H and C 1-4 alkyl
- X’ 1 , X’ 2 , X’ 3 , X’ 4 are selected from the following: (i) X’ 1 and X’ 2 are N and X’ 3 and X’ 4 are C independently substituted with Y’; (ii) X’ 1 and X’ 4 are N and X’ 2 and X’ 3 are C independently substituted with Y’; (iii) X’ 1 and X’ 3 are N and X’; (iii) X’ 1 and X’ 3 are N and X’; (iii)
- C 1-4 alkyl means an unsubstituted or optionally substituted straight or branched alkyl chain
- Aryl means unsubstituted or optionally substituted phenyl or naphthyl
- Hetaryl means an unsubstituted or optionally substituted 5- or 6-membered heteroaromatic ring containing one or more heteroatoms selected from O, N, S
- Cycloalkyl means a 3-8 membered saturated ring
- Cyclohetalkyl means an optionally substituted 3-8 membered saturated ring containing 1-3 heteroatoms selected from O, S, NR 24 , where R 24 is H, C 1-4 alkyl, aryl, hetaryl.
- the method comprises administering to a subject in need of treatment an amount of at least one compound of the general formula (VI) selected from the group consisting of:
- the methods comprise administering a compound of the structure: (TXR-311, or compound 24).
- Compound 24, or (S)-1-ethyl-3-(2-methoxy-4-(5-methyl-4-((1-(pyridin-3- yl)butyl)amino)pyrimidin-2-yl)phenyl)urea is also identified as CYT997 (Lexibulin), a microtubule targeting agent reported previously in Bioorg Med Chem Lett 19:4639–4642, 2009; Mol Cancer Ther 8:3036–3045, 2009.
- the methods treat a subject who has HCC.
- the disclosure provides for the use of the compounds disclosed herein for the treatment of liver cancer.
- the disclosure relates to the use of compounds of general formula (I) in the treatment of liver cancer.
- the disclosure relates to the use of compounds of general formula (II) in the treatment of liver cancer.
- the disclosure relates to the use of compounds of general formula (III) in the treatment of liver cancer.
- the disclosure relates to the use of compounds of general formula (IV) in the treatment of liver cancer.
- the disclosure relates to the use of compounds of general formula (V) in the treatment of liver cancer.
- the disclosure relates to the use of compounds of general formula (VI) in the treatment of liver cancer.
- the compound may be selected from any of compounds (1)- (24).
- the disclosure relates to the use of compound 24 for the treatment of liver cancer.
- the use relates to the treatment of HCC.
- the disclosure provides for the use of compound 24 in the treatment of HCC.
- Patients and Subjects Amenable to Treatment [80]
- the methods disclosed above relate to the treatment of a mammalian subject and preferably relate to methods for treating a human patient who has liver cancer.
- HCC liver cancer
- the goals of a tumor staging system in HCC are to estimate a patient’s prognosis, which allows for appropriate therapy to be selected.
- the identification of that appropriate therapy in turn, requires a staging paradigm that standardizes the platform for researchers to exchange data regarding treatments and outcomes.
- HCC staging systems with respect to their development and limitations are commonly utilized. These staging systems include TNM, Okuda staging, BCLC staging classification, Child-Pugh score, Japan integrated staging, Chinese University Prognostic Index (CUPI), and the French scoring system (GRETCH).
- the Okuda system is a prognostic score introduced in 1985 and incorporates both tumor features as well as the degree of underlying cirrhosis.
- a staging system based on four factors representing advanced disease. This includes tumor occupying greater or less than 50% of the liver, the presence or absence of ascites, and serum albumin and bilirubin levels (Table 1).
- median survival was 11.5 months for Stage I, 3.0 months for Stage II and 0.9 months for Stage III.
- the Child-Pugh score is a scoring system to measure the severity of chronic liver disease inclusive of cirrhosis. The intention is to provide a system with which clinicians can objectively communicate about liver function. (See, e.g., Subramaniam et al., Chin Clin Oncol (2013) 2(4):33.) Table 1. Okuda staging [83] Among the above seven staging systems, BCLC is used by many practitioners to guide clinical decision-making, because of its widespread presence in contemporary HCC research.
- BCLC The BCLC classification was first published in 1999 and is considered the standard HCC system by the American Association of for the Study of Liver Disease (AASLD) and European Association for the Study of the Liver. (See, e.g., Subramaniam et al., Chin Clin Oncol (2013) 2(4):33.)
- AASLD American Association of for the Study of Liver Disease
- EAK European Association for the Study of the Liver.
- BCLC takes into account size and extent of the primary tumor, liver function and physiological factors and incorporates the Okuda stage and Child-Pugh score (Table 2).
- There is a corresponding treatment schedule for each stage (Table 3), ranging from curative therapies such as resection or transplant for early stage patients to best supportive care for end-stage patients. (See, e.g., Subramaniam et al., Chin Clin Oncol (2013) 2(4):33.) Table 2.
- BCLC Barcelona Clinic Liver Cancer
- HCC hepatocellular carcinoma
- Signs and symptoms of HCC may include: • Pain in the upper right part of your belly • A lump or feeling of heaviness in your upper belly • Bloating or swelling in your belly • Loss of appetite and feelings of fullness • Weight loss • Weakness or deep fatigue • Nausea and vomiting • Yellow skin and eyes • Pale, chalky bowel movements and dark urine • Fever [86] Although the mainstay of therapy for HCC is surgical resection, the majority of patients are not eligible because of tumor extent or underlying liver dysfunction.
- TACE transcatheter arterial chemoembolization
- Subjects amenable to treatment include subjects having a diagnosis of probable or possible hepatocellular carcinoma, or who do not yet meet such criteria but have sufficient sign(s), symptom(s), or genetic risk factor(s) of hepatocellular carcinoma as to place them at a statistically significant risk of developing hepatocellular carcinoma relative to the general population.
- Treatment In subjects already exhibiting a sign(s) and/or symptom(s) of liver cancer such as HCC, for example, administration of the compounds, compositions, and formulations disclosed herein can reverse, halt, or delay progression of disease (e.g., HCC) and/or reduce the severity of the clinical sign(s) or symptom(s) associated with liver cancer such as HCC.
- HCC a sign(s) and/or symptom(s) of liver cancer
- Some subjects are asymptomatic, but have one or more risk factors or may be at an early stage of the condition(s). In such subjects, administration of the compounds disclosed herein can inhibit or delay onset or progression of a condition to later stage and/or reduce the severity of the condition, once present.
- the methods may include administration of the compounds at a dosage level that is appropriate based on a number of factors, including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the subject undergoing therapy.
- Dosages may generally be in a range of about 0.01 to about 500 mg per kg patient body weight per day which can be administered in single or multiple doses.
- the dosage level can range from about 0.1 to about 250 mg/kg per day; or from about 0.5 to about 100 mg/kg per day; or from about 0.1 to about 50 mg/kg per day.
- the dosage may be about 0.05 to 0.5, about 0.5 to 5, or about 5 to 50 mg/kg per day.
- the methods can include any route of administration.
- the compounds or compositions can be provided in the form of tablets containing 1.0 to 1000 milligrams of the active ingredient, (e.g., 1.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of the active ingredient) for the symptomatic adjustment of the dosage to the patient to be treated.
- the active ingredient e.g., 1.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of the active ingredient
- the compounds may be administered on a regimen of 1 to 4 times per day (e.g., including twice or three times per day).
- the compounds used in the methods herein may be administered by any suitable route, for example, orally, such as in the form of tablets, capsules, granules, suspensions, or powders; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intracisternal injection or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents.
- the compounds may, for example, be administered in a form suitable for immediate release or extended release as is generally known in the art.
- Combination Therapies [94] As discussed above, the methods disclosed herein can be used as a monotherapy for treatment or prophylaxis of liver cancer (e.g., HCC). In some embodiments of the above aspects, the disclosed methods of treatment can be used in combination with one or more additional therapeutic interventions. Non-limiting examples include radiation, surgery, immunotherapy, and other anti-cancer (i.e., anti-neoplastic) agents.
- the methods further comprise administration of the compounds disclosed above in combination with an additional anti-cancer agent that may be selected from the non-limiting examples of alkylating agents, antimetabolites, natural antineoplastic agents, hormonal antineoplastic agents, angiogenesis inhibitors, differentiating reagents, RNA inhibitors, antibodies or immunotherapeutic agents, gene therapy agents, small molecule enzymatic inhibitors, biological response modifiers, and anti-metastatic agents.
- an additional anti-cancer agent may be selected from the non-limiting examples of alkylating agents, antimetabolites, natural antineoplastic agents, hormonal antineoplastic agents, angiogenesis inhibitors, differentiating reagents, RNA inhibitors, antibodies or immunotherapeutic agents, gene therapy agents, small molecule enzymatic inhibitors, biological response modifiers, and anti-metastatic agents.
- a combination therapy can include sorafenib, which represents the current standard of care.
- Patent 7,981,900 which refers to a 2-step synthetic process starting from a dihaloheterocycle.
- the first step is a nucleophilic aromatic substitution to generate a monoamino- monohalo intermediate.
- the nucleophilic aromatic substitution can be carried out by addition of a primary or secondary amine to the di-halogenated heterocycle in an organic solvent (e.g., alcohols, aliphatic and cyclic ethers, ethanol, DMF, toluene, or xylene).
- an organic solvent e.g., alcohols, aliphatic and cyclic ethers, ethanol, DMF, toluene, or xylene.
- the reaction is typically performed at elevated temperature in the presence of excess amine or a non-nucleophilic base such as triethylamine or diisopropylethylamine, or an inorganic base such as potassium carbonate or sodium carbonate.
- a non-nucleophilic base such as triethylamine or diisopropylethylamine, or an inorganic base such as potassium carbonate or sodium carbonate.
- the amino substituent may be introduced through a transition metal catalyzed amination reaction, using catalysts such as Pd(OAc) 2 /P(t-Bu) 3 , Pd 2 (dba) 3 /BINAP and Pd(OAc) 2 /BINAP.
- the amines employed in the first step of the synthesis of these compounds are obtained commercially or are prepared using methods well known to those skilled in the art (e.g., ⁇ -alkylbenzylamines prepared through reduction of oximes using reductants known in the art).
- the ⁇ -alkylbenzylamines may also be prepared using known methods, such as for example reductive amination of ketones (e.g., the Leuckart-Wallach reaction) or from ⁇ -alkylbenzyl alcohols.
- the second step of the synthesis involves cross-coupling of the monoamino- monohalo intermediate with a functionalized coupling reagent, typically using palladium.
- Typical coupling reagents can include those used in Suzuki coupling (boronic acids or esters, see e.g., Miyaura, N. and Suzuki, Chem. Rev. 1995, 952457); Stille coupling (tin hydrides, see e.g., Stifle, J. K., Angew. Chem., Int. Ed.
- Example 1 Identifying candidate compounds using in vitro cytotoxicity assays in human hepatocellular carcinoma cells and primary human hepatocytes
- a set of structurally diverse candidate compounds were identified for investigation based on existing available information using a process that combines an initial computational- based analysis and review of existing information available for candidate compounds with additional research and development of the identified candidate compounds specifically directed to determine the efficacy of the compounds in the treatment of liver cancer.
- five human HCC cell lines were used in a cell proliferation assay study: HepG2, Hep3B, Hep40, Huh7 and PLC/PRF/5 (PLC5).
- All cell lines were obtained from either the American Type Culture Collection (ATCC; Manassas, VA) or provided as a gift. Cells were maintained in Dulbecco’s Modified Eagle’s Medium, 10% fetal calf serum and penicillin/streptomycin. Cells were cultured at 37°C in a humidified atmosphere with 5% CO2. [103] A stock solution (10 mM in DMSO, 100%) was prepared for each screened candidate compound. Cells were seeded at 5000 cells per well in 96-well plates and allowed to adhere overnight. Compounds were then added at the desired final concentrations, and incubated for an additional 72 hours before cell proliferation was assessed.
- ATCC American Type Culture Collection
- VA Manassas, VA
- a stock solution (10 mM in DMSO, 100%) was prepared for each screened candidate compound. Cells were seeded at 5000 cells per well in 96-well plates and allowed to adhere overnight. Compounds were then added at the desired final concentrations, and incubated for an
- Liver cytotoxicity was assessed using three primary human hepatocytes: HU1767, HU8216, and HU8264 (purchased from ThermoFisher Scientific (Waltham, MA)) for candidate compounds identified from the HCC cell line assay, the compounds identified as TXR-311 (also identified as Compound 24 herein) and TXR-312.
- Cryopreserved hepatocytes were thawed using cryopreserved hepatocytes recovery medium. These cells were plated in 96-well plates and maintained in Williams’ Medium E and supplemented with hepatocyte maintenance supplement hPack (serum-free). Cells were cultured at 37°C in a humidified atmosphere with 5% CO 2 .
- hepatocyte toxicity assay a stock solution of (10 mM in 100% DMSO) was prepared for the selected candidate compounds. Cells were seeded at 30,000 cells per well in 96- well plates and allowed to adhere overnight. Compounds were then added at the desired final concentrations, and incubated for an additional 72 hours before cell proliferation was assessed. [106] Two methods were used for the calculation of IC50: cell proliferation and cell viability assays. Both assays were performed using the respective commercial kits and in accordance with manufacturer’s protocol (CellTiter 96® AQueous One Solution Cell Proliferation kit and CellTiter-Glo® Luminescent Cell Viability Assay; (Promega; Madison, Wisconsin).
- the IC 50 was calculated based on an estimate of the anti-proliferative and cytotoxic effects observed in the cell proliferation and cell viability assays, respectively. [107] Results. [108] HCC toxicity. Two of the screened candidate compounds in the HCC cytotoxicity assay were selected for evaluation in the hepatocyte toxicity assays based on calculated IC 50 values (0.044 ⁇ 0.019 ⁇ M; and 5.5 ⁇ 1.53 ⁇ M). Data for the two selected compounds, TXR-311 and TXR-312, were obtained in triplicate for each cell line at each concentration. The mean IC50 for each selected compound and for each cell line was calculated and presented in Tables 4 and 5.
- IC 50 for each selected compound was calculated and presented in Table 6 and plotted in Figures 1A-1E.
- Hepatocyte toxicity The cytotoxicity of each selected compound was tested in primary human hepatocytes. The results are summarized in Table 7 and plotted in Figure 2.
- One of the selected compounds, TXR-311 had a significantly higher IC50 ( ⁇ 540 fold) observed in hepatocytes compared to the IC 50 in HCC cell lines (23.62 ⁇ 5.9 ⁇ M compared to 0.044 ⁇ 0.018 ⁇ M, respectively), indicating that its activity has a high selectivity for HCC tumor cells with very low toxicity to normal liver cells.
- Example 2 Maximum tolerated dose (MTD) study in BALB/c mice [110] Twenty female/male BALB/c mice of approximately 8-10 weeks of age and weighing 26-29 grams each at the time of dosing were used in a dose range-finding study. Animals were acclimated for 5 days prior to dose administration. The animals were group-housed in sterilized plastic “shoebox” cages with microisolator caps in a single room dedicated to rodents. LabDiet® 5001 Rodent Diet (Purina Mills, Inc.; St.
- mice with HCC patient-derived tumor xenografts Female/male NSG mice (NOD scid gamma, NOD-scid IL2Rg null , NOD- scid IL2Rgamma null ) of approximately 8-10 weeks of age and weighing 27-33 g each at the time of dosing were obtained to establish two patient-derived xenograft (PDX) orthotopic tumor models.
- the animals were group housed (n ⁇ 5) in sterilized plastic “shoebox” cages with microisolator caps in a single room dedicated to immunocompromised rodents.
- PDX1 was derived from a patient with non-viral HCC with cirrhosis and metastasis to intra-abdominal lymph nodes.
- the tumor was diagnosed as a moderately-differentiated HCC, stage 1.
- PDX2 was derived from a patient with HBV-associated HCC, with cirrhosis and vascular invasion.
- the tumor was diagnosed as being poorly- differentiated HCC, stage 2. Both patients gave informed consent to have their tissue specimens used for research studies.
- PDX1 typically has a faster growth rate (about double) compared to PDX2. There are no known genetic mutations for each PDX tumor.
- the PDX1 study was performed in 18 tumor-bearing NSG mice, consisting of two groups of nine mice per group.
- the PDX2 study was performed in 20 tumor-bearing NSG mice, consisting of two groups of seven mice per group and one group of six mice. Both PDX1 and PDX2 cells were labeled with the luciferase reporter gene using a lenti-virus expression vector. Approximately one month before the projected start of each of the PDX studies, two mice from each PDX cohort were implanted with tumor cells. Implantation was performed via subcutaneous (SC) injection into the cephalad dorsum area with 0.1 mL ( ⁇ 5 x 10 6 cells) per mouse.
- SC subcutaneous
- the tumors cells were administered as a single-cell suspension of each of the PDX cells suspended in 50% Matrigel (BD Biosciences; Bedford, MA) in phosphate-buffered saline (PBS). Following implantation, mice were returned to their cages and tumors were allowed to develop, for up to 28-42 days, depending on the growth rate of the tumors. Tumor growth was monitored once weekly using Xenogen IVIS in vivo imaging system. Luciferase images were acquired following intraperitoneal injection (IP) of D-luciferin substrate. [117] Donor animals were sacrificed once tumors had reached the desired diameter of ⁇ 100 mm.
- IP intraperitoneal injection
- the tumor was then removed and dissected into ⁇ 2 mm 3 fragments and surgically implanted into the left lobe of the liver in NSG mice. Starting on Day 0 (7 days after tumor implantation) and for a total of up to 42 consecutive days.
- the in-life study performed as two cohorts as shown in Table 11.
- animals implanted with PDX1 were dosed tri- weekly (Q3W) with TXR-311 or vehicle.
- animals implanted with PDX2 were dosed tri-weekly (Q3W) with TXR-311 or vehicle and 5 times a week with sorafenib.
- mice were dosed via oral gavage (PO) at 5 mL/kg with vehicle, TXR-311, (both on M/W/F each week) or sorafenib (on M/T/W/Th/F each week) as specified in Table 11.
- PO oral gavage
- TXR-311 both on M/W/F each week
- sorafenib on M/T/W/Th/F each week
- Table 11 All mice were dosed via oral gavage (PO) at 5 mL/kg with vehicle, TXR-311, (both on M/W/F each week) or sorafenib (on M/T/W/Th/F each week) as specified in Table 11.
- TXR-311 both on M/W/F each week
- sorafenib on M/T/W/Th/F each week
- PDX1 study Tumor size was monitored weekly using IVIS imaging. The luciferase counts for each animal during the in-life period (Days 0-25) are presented in Table 13 and plotted in Figure 6; IVIS images are presented in Figures 7-8. By the end of in-life period (Day 25) the tumors of TXR-311-treated animals were 3-fold smaller compared to vehicle-treated animals. This inhibition in tumor growth was statistically significant when compared to vehicle- treated animals (p ⁇ 0.001, 2-way ANOVA). [122] Body weight data are provided in Table 12 and plotted in Figure 5.
- mice bearing the PDX1 tumor which were treated with vehicle or 20 mg/kg of TXR-311 exhibited a decrease in body weight during the in-life period.
- animals treated with vehicle showed a 26% body weight loss and animals treated with TXR-311 showed a 18% body weight loss when compared to the average body weight at Day 0.
- Statistical analysis (2-way ANOVA) indicated that the difference in body weight change between treatment groups was not significant (p > 0.05). Due to the severe decrease in body weight along with large tumor dimensions, all mice were sacrificed on Day 25. Table 12.
- PDX1 - Tumor Growth and Luciferase Counts [123] PDX2 study: Tumor size was monitored weekly using IVIS. The luciferase counts for each animal during the in-life period (Days 0-42) is presented in Table 15 and plotted in Figure 12; IVIS images are presented in Figures 13-22. By the end of in-life period (Day 42) animals treated with TXR-311 or sorafenib had tumors that were 4 times smaller compared to vehicle- treated animals. This inhibition in tumor growth was statistically significant when compared to vehicle treated animals (p ⁇ 0.001, 2-way ANOVA).
- mice treated with TXR-311 exhibit a mean tumor volume of 805 ⁇ 187 mm 3 while animals treated with vehicle show a larger mean tumor volume of 1876 ⁇ 218 mm 3 .
- animals treated with TXR-311 had the lowest tumor volume when compared to vehicle- and sorafenib-treated animals: 750 ⁇ 410 mm 3 vs 2193 ⁇ 688 mm 3 , and 1082 ⁇ 485 mm 3 , respectively.
- TXR-311 Measuring the tumor volume at the time of necropsy showed a significant decrease in PDX1 but not in PDX2 xenograft when compared to vehicle-treated animals. Based on luciferase counts of in-life xenografts, TXR-311 reduced PDX1 and PDX2 tumor volume by 3- and 4-fold, respectively at the end of the treatment period. [128] In summary, preclinical cytotoxicity studies and patient derived xenograft animal model studies of TXR-311 suggest that certain CBS microtubule destabilizing agents constitute a class of drug candidates for the treatment of liver cancers such as HCC and possesses specificity for tumorigenic cells relative to normal hepatocytes.
Abstract
The disclosure provides methods of treating liver cancers including hepatocellular carcinoma in a subject in need of treatment, where the methods comprise administration of a compound or a composition or formulation comprising a compound of Formulas (I), (II), (III), (IV), (V), and (VI) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof.
Description
THERAPEUTIC AGENTS FOR TREATING HEPATOCELLULAR CARCINOMA PRIORITY [1] This application claims priority to U.S. Provisional patent application serial number 63/110,148, filed November 5, 2020, which is incorporated herein by reference in its entirety. BACKGROUND [2] Liver cancer is a difficult-to-treat disease at least in part because it is not often identified at an early stage. Most common treatments focus on slowing progress of the disease, extending patient survival and improving quality of life. Hepatocellular carcinoma (HCC), also called malignant hepatoma, is the most common type of liver cancer. Most cases of HCC are secondary to either a viral hepatitis infection (hepatitis B or C) or cirrhosis (alcoholism being the most common cause of liver cirrhosis). [3] HCC is now the third leading cause of cancer deaths worldwide, with over 500,000 people affected (Global Data - HEPATOCELLULAR CARCINOMA – OPPORTUNITY ANALYSIS AND FORECASTS TO 2024, pg.21). The incidence of HCC is highest in Asia and Africa, where the endemic high prevalence of hepatitis B and hepatitis C strongly predisposes to the development of chronic liver disease and subsequent development of HCC. Each year in the United States, approximately 15,000 men and 6,000 women are diagnosed with primary liver cancer. [4] The presentation of HCC has evolved significantly over the past few decades. Whereas in the past, HCC generally presented at an advanced stage with right-upper-quadrant pain, weight loss, and signs of decompensated liver disease, it is now increasingly recognized at a much earlier stage as a consequence of the routine screening of patients with known cirrhosis, using cross-sectional imaging studies and serum alpha-fetoprotein (AFP) measurements. [5] The occurrence of HCC is expected to continue to grow in the coming years. The peak incidence of HCC associated with hepatitis C virus (HCV) infection has not yet occurred. There is also a growing problem with cirrhosis, which develops in the setting of nonalcoholic fatty liver disease (NAFLD), or nonalcoholic steatohepatitis (NASH). NASH typically develops in the setting of obesity, type 2 diabetes, dyslipidemia, and hypertension, and it remains a
significant problem. Thus, developing effective and efficient care for patients with end-stage liver disease and HCC must become a significant focus. [6] Successful treatments for HCC have been limited (Bruix J, et al. J Hepatol 35:421- 430, 2001; Bruix J, et al. Cancer Cell 5:215-219, 2004; Haskell C M. Chapter 46 Liver: Natural History, Diagnosis and Staging in "Cancer Treatment" 5th edition, W. B, Saunders Company, Philadelphia, editors: Haskell C M & Berek J S; Szklaruk J, et al. AJR 180:441-453, 2003). Despite active therapy, survival rates of patients with HCC in the U.S. are among the lowest of all cancer patients (ACS Cancer Facts & Figures (2017)). Thus, there is an urgent need to develop and identify therapeutics that are specific and more effective in the treatment of liver cancers such as HCC. SUMMARY [7] In one aspect, the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (I):
or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: R1 is H, C1-4 alkyl; Q is a bond, or C1-4 alkyl; A is aryl, heteroaryl optionally substituted with 0-3 substituents independently chosen from halogen, C1-4 alkyl, CH2F, CHF2, CF3, CN, aryl, hetaryl, OCF3, OC1-4alkyl, OC2- 5alkylNR4R5, O-aryl, O-hetaryl, CO2R4, CONR4R5, nitro, NR4R5, C1-4 alkylNR4R5, NR6C1-4alkylNR4R5, NR4COR5, NR6CONR4R5, NR4SO2R5; R4, R5 are each independently H, C1-4 alkyl, C1-4 alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, aryl, hetaryl, C1-4alkyl aryl, C1-4 alkyl hetaryl, or may be joined to form an optionally
substituted 3-8 membered ring optionally containing an atom selected from O, S, NR7; R6 is selected from H, C1-4 alkyl; R7 is selected from H, C1-4 alkyl, aryl, hetaryl, C1-4alkyl aryl, C1-4 alkyl hetaryl; R2 is 0-2 substituents independently selected from halogen, C1-4alkyl, OH, OC1-4alkyl, CH2F, CHF2, CF3, OCF3, CN, C1-4alkylNR8R9, OC1-4alkylNR8R9, CO2R8, CONR8R9, NR8R9, NR8COR9, NR10CONR8R9, NR8SO2R9; R8, R9 are each independently H, C1-4 alkyl, C1-4 alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, aryl, hetaryl, C1-4 alkyl aryl, C1-4 alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR11; R10 is selected from H, C1-4 alkyl, aryl or hetaryl; R11 is selected from H, C1-4 alkyl, aryl, hetaryl, C1-4alkyl aryl, C1-4 alkyl hetaryl; Y is halogen, OH, NR12R13, NR14COR12, NR14CONR12R13, N14SO2R13; R12 and R13 are each independently H, CH2F, CHF2, CF3, CN, C1-4 alkyl optionally substituted with OH, OC1-4alkyl or NR15R16 , cycloalkyl; cyclohetalkyl, C1-4 alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, or may be joined to form an optionally substituted 3-6 membered ring optionally containing an atom selected from O, S, NR14; R14, R15 and R16 are each independently selected from H, C1-4 alkyl; n=0-4; W is selected from H, C1-4alkyl, C2-6alkenyl; where C1-4alkyl or C2-6alkenyl may be optionally substituted with C1-4alkyl, OH, OC1-4alkyl, NR15R16; R15, and R16 are each independently H, C1-4 alkyl, C1-4alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR17; and R17 is selected from H, C1-4 alkyl. [8] In another aspect, the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (II):
or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: R1 is H, C1-4 alkyl; Q is a bond, or C1-4 alkyl; A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C1-4 alkyl, CH2F, CHF2, CF3, CN, aryl, hetaryl, OCF3, OC1-4alkyl, OC2- 5alkylNR4R5, O-aryl, O-hetaryl, CO2R4, CONR4R5, nitro, NR4R5, C1-4 alkylNR4R5, NR6C1-4alkylN R4R5, NR4COR5, NR6CON R4R5, NR4SO2R5; R4, R5 are each independently H, C1-4 alkyl, C1-4 alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, aryl, hetaryl, C1-4alkyl aryl, C1-4 alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR7; R6 is selected from H, C1-4 alkyl; R7 is selected from H, C1-4 alkyl, aryl, hetaryl, C1-4alkyl aryl, C1-4 alkyl hetaryl; R2 is 0-2 substituents independently selected from C1-4alkyl and OC1-4alkyl; Y is CH2OH, OC1-4alkylOH, OC1-4alkylR12, OC1-4alkylNR12NR13, C(O)R12 , CH2R12, COOR12, CONR12R13, OCON R12R13, CH2N R12R13, NHCOR12, NHCON R12 R13, R12 and R13 are each independently H, C1-2 alkyl, (CH2)3NEt2, (CH2)2NMe2, (CH2)5NH2, (CH2)2OH,
W is selected from H, C1-4alkyl, C2-6alkenyl; where C1-4alkyl or C2-6alkenyl may be optionally substituted with C1-4alkyl, OH, OC1-4alkyl, NR15 R16; R15, and R16 are each independently H, C1-4 alkyl, C1-4alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR17 R17 is selected from H, C1-4 alkyl; and wherein when Y is CH2R12 then R12 is not H, C1-2alkyl. [9] In another aspect, the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (III):
or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: X1, X2, X3, X4 are selected from the following:
(i) X1 and X2 are N and X3 and X4 are C independently substituted with Y; (ii) X1 and X4 are N and X2 and X3 are C independently substituted with Y; (iii) X1 and X3 are N and X2 and X4 are C independently substituted with Y; (iv) X2 and X4 are N and X1 and X3 are C independently substituted with Y; (v) X1 is N and X2, X3, and X4 are C independently substituted with Y; (vi) X3 is N and X1, X2, and X4 are C independently substituted with Y; (vii) X4 is N and X1, X2, and X3 are C independently substituted with Y; (viii) X2 is N and X1, X3, and X4 are C independently substituted with Y; and (ix) X1, X2 and X3 are N and X4 is C substituted with Y; R1 is H, C1-6alkyl, C1-6alkylNR5R6, C1-6alkylNR5COR6, C1-6alkylNR5SO2R6, C1-6alkylCO2R5, C1-6alkylCONR5R6; R5 and R6 are each independently H, C1-4alkyl, aryl, hetaryl, C1-4alkylaryl, C1- 4alkylhetaryl or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR7; R7 is selected from H, C1-4alkyl; R2 is selected from C1-6alkylOH, OC2-6alkylOH, C1-6alkylNR8R9, OC2-6alkylN R8R9, C1- 6alkylNR8COR9, OC2-6alkylNR8COR9, C1-6alkylhetaryl, OC2-6alkylhetaryl, OCON R8R9, NR8COOR9, NR10CONR8R9, CONR8R9, NR8COR12; R8, R9 are each independently H, C1-4alkyl, C1-4alkylNR11R13, hetaryl, cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR14; R12 is C2-4alkyl, C1-4alkylNR11R13, hetaryl, cyclohetalkyl; R11, R13 are each independently H, C1-4alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR14; R14 is selected from H, C1-4alkyl; R10 is H, C1-4 alkyl; R3 and R4 are each independently H, halogen, C1-4alkyl, OH, OC1-4alkyl, CF3, OCF3; Q is a bond, or C1-4 alkyl; W is selected from H, C1-4alkyl, C2-6alkenyl; where C1-4alkyl or C2-6alkenyl may be optionally substituted with C1-4alkyl, OH, OC1-4alkyl, NR15R16;
R15 and R16 are each independently H, C1-4alkyl, C1-4alkyl cycloalkyl, C1-4alkyl cyclohetalkyl, aryl, hetaryl, or may be joined to form an optionally substituted 3- 8 membered ring optionally containing an atom selected from O, S, NR17; R17 is selected from H, C1-4alkyl; A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C1-4 alkyl, CF3, aryl, hetaryl, OCF3, OC1-4alkyl, OC2-5alkylNR18R19, Oaryl, Ohetaryl, CO2R18, CONR18R19, NR18R19, C1-4 alkylNR18R19, NR20C1-4alkylNR18R19, NR18COR19, NR20CONR18R19, NR18 SO2R19; R18, R19 are each independently H, C1-4 alkyl, C1-4 alkyl cyclohetalkyl, aryl, hetaryl, C1- 4alkyl aryl, C1-4 alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21; R21 is selected from H, C1-4alkyl; R20 is selected from H, C1-4alkyl; Y is selected from H, C1-4alkyl, OH, NR22R23; and R22, R23 are each independently H, C1-4alkyl. [10] In another aspect, the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (IV):
or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: X1, X2, X3, X4 are selected from the following: (i) X1 and X2 are N and X3 and X4 are C independently substituted with Y; (ii) X1 and X4 are N and X2 and X3 are C independently substituted with Y; (iii) X1 and X3 are N and X2 and X4 are C independently substituted with Y; (iv) X2 and X4 are N and X1 and X3 are C independently substituted with Y;
(v) X1 is N and X2, X3, and X4 are C independently substituted with Y; (vi) X3 is N and X1, X2, and X4 are C independently substituted with Y; (vii) X4 is N and X1, X2, and X3 are C independently substituted with Y; (viii) X2 is N and X1, X3, and X4 are C independently substituted with Y; and (ix) X1, X2 and X3 are N and X4 is C substituted with Y; R1 is H, C1-6alkyl, C1-6alkylNR5R6, where R5 and R6 are each independently H, C1-4alkyl, aryl, hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR7;R7 is selected from H, C1-4alkyl; R2 is selected from C1-6alkylOH, OC2-6alkyl OH, C1-6alkylNR8R9, OC2-6alkyl NR8R9, C1- 6alkylNR8COR9, OC2-6alkylNR8COR9, C1-6alkylhetaryl, OC2-6alkylhetaryl, OCONR8R9, NR8COOR9, NR10CONR8R9, CONR8R9, NR8COR12; R8,R9 are each independently H, C1-4alkyl, C1-4alkylNR11R13, hetaryl, cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR14; R12 is C2-4alkyl, C1-4alkylNR11R13, hetaryl, cyclohetalkyl; R11, R13 are each independently H, C1-4alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR14; R14 is selected from H, C1-4alkyl; R10 is H, C1-4alkyl; R3 and R4 are each independently H, halogen, C1-4alkyl, OH, OC1-4alkyl, CF3, OCF3; Q is CH; W is selected from C1-4alkyl, C2-6alkenyl; where C1-4alkyl or C2-6alkenyl may be optionally substituted with C1-4alkyl, OH, OC1-4alkyl, NR15R16; R15, and R16 are each independently H, C1-4alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR17; R17 is selected from H, C1-4alkyl; A is aryl, hetaryl optionally substituted with 0-2 substituents independently chosen from halogen, C1-4alkyl, CF3, aryl, hetaryl, OCF3, OC1-4alkyl; OC2-3alkylNR18R19, Oaryl, Ohetaryl, CO2R18, CONR18R19, NR18R19, C1-4alkylNR18R19, NR20C1-4alkylNR18R19, NR18COR19, NR20CONR18R19, NR18SO2R19;
R18, R19 are each independently H, C1-4alkyl, C1-4alkyl cyclohetalkyl, aryl, hetaryl, C1- 4alkyl aryl, C1-4alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21; R21 is selected from H, C1-4alkyl; R20 is selected from H, C1-4alkyl; Y is selected from H, C1-4alkyl, NR22R23; and R22, R23 are each independently H, C1-4alkyl. [11] In another aspect, the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (V):
or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: X1, X2, X3, X4 are selected from the following: (i) X1 and X2 are N and X3 and X4 are C independently substituted with Y; (ii) X1 and X4 are N and X2 and X3 are C independently substituted with Y; (iii) X2 and X4 are N and X1 and X3 are C independently substituted with Y; (iv) X1 is N and X2, X3, and X4 are C independently substituted with Y; (v) X3 is N and X1, X2, and X4 are C independently substituted with Y; (vi) X4 is N and X1, X2, and X3 are C independently substituted with Y; (vii) X2 is N and X1, X3, and X4 are C independently substituted with Y; and (viii) X1, X2 and X3 are N and X4 is C substituted with Y; R1 is H, C1-6alkyl, C1-6 alkylNR5R6, C1-6alkylNR5COR6, C1-6alkylNR5SO2R6, C1-6alkylCO2R5, C1-6alkylCONR5R6;
R5 and R6 are each independently H, C1-4alkyl, aryl, hetaryl, C1-4alkylaryl, C1- 4alkylhetaryl or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR7; R7 is selected from H, C1-4alkyl; R2 is selected from OH, OC1-6alkyl, C1-6alkylOH, OC2-6alkylOH, C1-6alkylNR8R9, OC2- 6alkylNR8R9, C1-6alkylNR8COR9, OC2-6alkylNR8COR9, C1-6alkylhetaryl, OC2- 6alkylhetaryl, OCONR8R9, NR8COOR9, NR10CONR8R9, CONR8R9, NR8COR12; R8, R9 are each independently H, C1-4alkyl, C1-4alkylNR11R13, hetaryl, cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR14; R12 is C2-4alkyl, C1-4alkylNR11R13, hetaryl, cyclohetalkyl; R11, R13 are each independently H, C1-4alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR14; R14 is selected from H, C1-4alkyl; R10 is H, C1-4 alkyl; R3 and R4 are each independently H, halogen, C1-4alkyl, OH, OC1-4alkyl, CF3, OCF3; Q is a bond, or C1-4alkyl; W is selected from H, C1-4alkyl, C2-6alkenyl; where C1-4alkyl or C2-6alkenyl may be optionally substituted with C1-4alkyl, OH, OC1-4alkyl, NR15R16; R15, and R16 are each independently H, C1-4alkyl, C1-4alkyl cycloalkyl, C1-4alkyl cyclohetalkyl, aryl, hetaryl, or may be joined to form an optionally substituted 3- 8 membered ring optionally containing an atom selected from O, S, NR17; R17 is selected from H, C1-4alkyl; A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C1-4 alkyl, CF3, aryl, hetaryl, OCF3, OC1-4alkyl, OC2-5alkylNR18R19, Oaryl, Ohetaryl, CO2R18, CONR18R19, NR18R19, C1-4 alkylNR18R19, NR20C1-4alkylNR18R19, NR18COR19, NR20CONR18R19, NR18SO2R19; R18, R19 are each independently H, C1-4 alkyl, C1-4 alkyl cyclohetalkyl, aryl, hetaryl, C1- 4alkyl aryl, C1-4 alkyl hetaryl, or may be joined to form an optionally substituted 3- 8 membered ring optionally containing an atom selected from O, S, NR21;
R21 is selected from H, C1-4 alkyl; R20 is selected from H, C1-4 alkyl; Y is selected from H, C1-4alkyl, OH, NR22R23; R22, R23 are each independently H, C1-4 alkyl. [12] In another aspect, the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (VI):
or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: R’1 is C1-4 alkyl, R’2 is independently selected from the group consisting of: OH, NHCOR’12, and NHCONHR’12; R’12 is independently selected from the group consisting of H, C1-4 alkyl optionally substituted with OH, OC1-4alkyl or NR’15R’16; R’15 and R’16 are each independently selected from H and C1-4 alkyl; X’1, X’2, X’3, X’4 are selected from the following: (i) X’1 and X’2 are N and X’3 and X’4 are C independently substituted with Y’; (ii) X’1 and X’4 are N and X’2 and X’3 are C independently substituted with Y’; (iii) X’1 and X’3 are N and X’2 and X’4 are C independently substituted with Y’; (iv) X’2 and X’4 are N and X’1 and X’3 are C independently substituted with Y’; Y’ is selected from H, OH, C1-4alkyl, and OC1-4alkyl; X’5 is selected from N and C, and
when X’5 is C, R’6 is selected from the group H, halogen, C1-4 alkyl, OC1-4alkyl, CF3, and OCF3: R’5 is selected from the group C1-4 alkyl, OC1-4alkyl, CF3, and OCF3; and R’7 is selected from the group H, halogen, C1-4 alkyl, OC1-4alkyl, CF3, and OCF3. [13] In another aspect, the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment a compound of the general formula (VI) that is selected from the group consisting of:
or a pharmaceutically acceptable prodrug, salt, hydrate, solvate, or crystal form thereof. [14] In another aspect, the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment a compound having the structure:
or a pharmaceutically acceptable prodrug, salt, hydrate, solvate, or crystal form thereof. [15] In some embodiments of the above aspects, the method can treat a liver cancer that is selected from the group consisting of hepatocellular carcinoma (HCC), fibrolamellar HCC, bile duct cancer, angiosarcoma, and secondary liver cancer. In yet further embodiments, the method may treat HCC. [16] In some embodiments of the above aspects, the subject may be a mammal that has a liver cancer. In some further embodiments, the subject is a human who has liver cancer. [17] In some embodiments of the above aspects, the methods can further comprise monitoring the subject for a change in a sign and/or a symptom of liver cancer that is responsive to administering the compound. [18] In some embodiments, the methods of treatment may be administered as a monotherapy. In alternative embodiments, the methods of treatment may be administered as part of a combination therapy and can further comprise one or more additional therapeutic interventions. In some further embodiments, the methods of treatment may further comprise
surgery. In some further embodiments, the methods of treatment may further comprise administration of at least one additional anti-cancer agent. [19] In some embodiments of the above aspects, the compound can be administered intravenously, subcutaneously, or orally. [20] In some further aspects, the disclosure provides for the use of the compounds disclosed herein, or a pharmaceutically acceptable prodrug, salt, hydrate, solvate, or crystal form thereof, for the treatment of a liver cancer. [21] In another further aspect, the disclosure provides for the use of the compounds disclosed herein, or a pharmaceutically acceptable prodrug, salt, hydrate, solvate, or crystal form thereof, for the preparation of a medicament for the treatment of a liver cancer. [22] In embodiments of these further aspects, the use can be for the treatment of a liver cancer selected from the group consisting of: hepatocellular carcinoma (HCC), fibrolamellar HCC, bile duct cancer, angiosarcoma, and secondary liver cancer. In yet further embodiments the liver cancer is HCC. [23] Other features, aspects, embodiments, and advantages provided by the disclosure will be apparent from the detailed description that follows. BRIEF DESCRIPTION OF THE DRAWINGS [24] Figures 1A-1E depict viability for individual HCC cell lines HepG2 (Figure 1A); Hep3B (Figure 1B); Hep40 (Figure 1C); Huh7 (Figure 1D); and PLC5 (Figure 1E) as a function of candidate compound concentration. [25] Figure 2 depicts IC50 summary information for candidate compounds in HCC cell lines and primary human hepatocytes. [26] Figure 3 depicts the maximum tolerated dose survival curve for TXR-311 in BALB/c mice. [27] Figure 4 depicts body weight changes in maximum tolerated dose assays for different concentrations of TXR-311. [28] Figure 5 depicts body weight changes in the PDX1 cohort for animals treated with TXR-311 relative to vehicle.
[29] Figure 6 depicts tumor measurement in the PDX1 cohort for animals treated with TXR-311 relative to vehicle. [30] Figure 7 depicts tumor images (IVIS) for animals in the PDX1 cohort that were treated with vehicle [31] Figure 8 depicts tumor images (IVIS) for animals in the PDX1 cohort that were treated with TXR-311. [32] Figure 9 depicts differences in tumor size on Day 25 for animals in the PDX1 cohort for animals treated with TXR-311 relative to vehicle. [33] Figure 10 depicts the difference in tumor volume in the PDX1 cohort for animals treated with TXR-311 relative to vehicle. [34] Figure 11 depicts the body weight in the PDX2 cohort for animals treated with TXR- 311 or sorafenib relative to vehicle. [35] Figure 12 depicts the IVIS-derived tumor measurement in the PDX2 cohort for animals treated with TXR-311 or sorafenib relative to vehicle. [36] Figure 13 depicts tumor images (IVIS) for animals in the PDX2 cohort that were treated with vehicle, TXR-311, or sorafenib at Day 0. [37] Figure 14 depicts tumor images (IVIS) for animals in the PDX2 cohort that were treated with vehicle, TXR-311, or sorafenib at Day 7. [38] Figure 15 depicts tumor images (IVIS) for animals in the PDX2 cohort that were treated with vehicle, TXR-311, or sorafenib at Day 14. [39] Figure 16 depicts tumor images (IVIS) for animals in the PDX2 cohort that were treated with vehicle, TXR-311, or sorafenib at Day 21. [40] Figure 17 depicts tumor images (IVIS) for animals in the PDX2 cohort that were treated with vehicle, TXR-311, or sorafenib at Day 28. [41] Figure 18 depicts tumor images (IVIS) for animals in the PDX2 cohort that were treated with vehicle, TXR-311, or sorafenib at Day 35. [42] Figure 19 depicts tumor images (IVIS) for animals in the PDX2 cohort that were treated with vehicle, TXR-311, or sorafenib at Day 42. [43] Figure 20 depicts tumor images (IVIS) summarizing tumor growth for animals in the PDX2 cohort that were treated with vehicle.
[44] Figure 21 depicts tumor images (IVIS) summarizing tumor growth for animals in the PDX2 cohort that were treated with TXR-311. [45] Figure 22 depicts tumor images (IVIS) summarizing tumor growth for animals in the PDX2 cohort that were treated with sorafenib. [46] Figure 23 depicts differences in tumor size for animals in the PDX2 cohort that were treated with vehicle, TXR-311, or sorafenib. [47] Figure 24 depicts a graphical summary of the tumor volume data for animals in the PDX2 cohort that were treated with vehicle, TXR-311, or sorafenib. DETAILED DESCRIPTION [48] The disclosure provides methods that are directed to the treatment of liver cancer that comprise administration of compounds and compositions that are identified through a process that combines an initial computational-based analysis of approved or investigational drugs using DUMA, a proprietary artificial intelligence platform, and reviewing existing information available for candidate compounds along with performing additional research and development of the identified candidate compounds specifically directed to determine the efficacy of the compounds in the treatment of liver cancer. Using this type of evaluation provides several advantages relative to conventional therapeutic agent discovery, including reduction in the overall cost and time of providing new treatments and therapies for particular diseases and conditions. The initial screening of candidate compounds that have existing human safety and pharmacodynamic data provides a reduced risk of expensive failures late in development due to safety concerns. [49] Therefore, in a general sense, the disclosure provides methods of treating liver cancer, including hepatocellular carcinoma (HCC), comprising administering to a subject in need of treatment certain 2-phenyl pyrazines that have been previously described as microtubule inhibitors, and that have now, for the first time, been shown to be effective in the treatment of liver cancer. [50] Microtubule binding agents include a broad range of structurally diverse compounds that can function to stabilize or destabilize the microtubule structure and assembly. Both stabilizing and destabilizing agents are used as clinically relevant anti-cancer drugs including
stabilizing agents such as docetaxel, paclitaxel, and ixabepilone, and destabilizing agents such as the alkaloids, vincristine, vindesine, and vinblastine. Microtubule binding agents that destabilize microtubule structure are usually classified based on the domain to which they bind, either the vinca-domain or the colchicine binding site (or “CBS”). Some agents that bind the vinca-domain (e.g., vincristine, vindesine, and vinblastine) have been developed as therapeutics against specific types of cancers (e.g., breast, ovarian). In contrast, and despite the existence of data that shows some CBS binding agents possess in vitro cytotoxicity against certain cancer cell lines, no CBS binding agents have yet been shown to be effective in the treatment of any cancers. [51] The instant disclosure and the Examples demonstrate, the inventor have identified a class of microtubule binding agents that target the colchicine binding site and are effective in the treatment of liver cancers including HCC in particular. Furthermore, the data demonstrates that the compounds identified and recited in the methods of treatment exert a specific cytotoxic effect against tumorigenic cells of the liver relative to normal hepatocytes. Definitions [52] Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. As used herein, the following terms have the meanings ascribed to them below, unless specified otherwise. [53] It should be appreciated that all numerical ranges disclosed herein are intended to include any particular number within that range as well as sub-ranges that fall within the scope of the broader range. For example, a range of 0.01% to 5.0% will be understood to also encompass ranges falling at or above 0.01% and at or below 5.0% (e.g., 3.7%, 1.0%, 0.02% - .04%, 0.02% - 4.5%, 0.05% - 4.08%, or 0.03% - 1.0%, etc). These are just examples of the types of numbers and ranges that would be encompassed. [54] The term “tissue” refers to an aggregate of multiple cells and/or cell products. [55] The “gene” refers to a nucleic acid sequence or portion thereof that encodes a protein. Nucleic acid sequences may include, but are not limited to, DNA in any form, such as genomic DNA, cDNA, synthesized DNA. Nucleic acid sequences may also include RNA and RNA transcripts corresponding to DNA.
[56] The terms “peptide,” “polypeptide” and “protein” refer interchangeably to a molecule comprised of amino acid residues covalently linked by peptide bonds. A protein or peptide may contain at least three amino acids, and no limitation may be placed on the maximum number of amino acids that can comprise a protein or peptide sequence. Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types. “Polypeptides” include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others. The polypeptides include natural peptides, recombinant peptides, synthetic peptides, or a combination thereof. [57] The terms “patient” and “subject” are used interchangeably to refer to animals that may be in need of a therapy that comprises the methods and compositions described herein. Non-limiting examples of animals that may be a patient or subject include animals such as primates (e.g., humans, and non-human primates, such chimpanzees, gorillas), and other mammals (e.g., cats, dogs, agricultural mammals, such as equines, bovines, ovines, porcines, horses, pigs, cows, sheep, laboratory rodents/animal model systems, such as hamsters, mice and rats, and rabbits). [58] A subject at risk of a condition includes subjects who by virtue of a known characteristic, such as a genetic marker, biomarker, existing disease or condition, or family history, are at a measurably or significantly higher risk (p ≤ 0.05) relative to a control population of individuals not known to have such genetic marker, biomarker or family history or the like, of developing the condition. Certain risk factors may be associated with occurrence and/or onset of liver cancer, and may be used to identify subject who may be at risk of developing liver cancer, or who may be screened for liver cancer prior to onset of any symptoms (i.e., clinical conditions) associated with liver cancer. Non-limiting examples of risk factors include hepatitis B or hepatitis C infections, cirrhosis of the liver caused by alcoholism, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH). [59] The term “disease” or “clinical conditions” refer to a physiological state of an organism with an abnormal biological state. Abnormal biological states include, but are not
limited to, an interruption, cessation or disorder of cells, tissues, body functions, systems or organs that may be inherent, inherited, caused by an infection (e.g., sepsis), caused by abnormal cell function, caused by abnormal cell division (e.g., cancer), and the like. As discussed in the aspects and embodiments herein, the methods relate to the treatment of liver cancer. [60] Liver cancer, as discussed herein, can refer broadly to any abnormal cell growth, neoplasm, or tumor in the liver. In embodiments of the methods disclosed herein, liver cancer relates to a malignant tumor or neoplasm and may include the non-limiting examples of hepatocellular carcinoma (HCC, or hepatoma), fibrolamellar HCC, cholangiocarcinoma (bile duct cancer), angiosarcoma (hemangiocarcinoma), and secondary liver cancer (metastasis to the liver, often (but not required to be) originating from colon or colorectal cancer). In certain embodiments, the liver cancer is HCC. In some embodiments, the liver cancer is a secondary liver cancer. [61] The phrase “pharmaceutically acceptable” refers to an agent that does not interfere with the effectiveness of the biological activity of an active ingredient, and which may be approved by a regulatory agency of the Federal government or a state government, or is listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly for use in humans. Accordingly, suitable pharmaceutically acceptable carriers include agents that do not interfere with the effectiveness of a pharmaceutical composition. [62] The phrase “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable, preferably nontoxic, acids and bases, including inorganic and organic acids and bases, including but not limited to, sulfuric, citric, maleic, acetic, oxalic, hydrochloride, hydro bromide, hydro iodide, nitrate, sulfate, bisulfite, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, fornate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., 1,1’-methylene-bis-(2-hydroxy-3- naphthoate)) salts. Pharmaceutically acceptable salts include those formed with free amino groups such as, but not limited to, those derived from hydrochloric, phosphoric, acetic, oxalic, and tartaric acids. Pharmaceutically acceptable salts also include those formed with free carboxyl groups such as, but not limited to, those derived from sodium, potassium, ammonium,
sodium lithium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, and procaine. [63] The terms “therapy” and “treatment” refer to those medical steps taken to alleviate or alter a disease state, e.g., a course of treatment intended to reduce or eliminate the affects or symptoms of a disease using pharmacological, surgical, dietary and/or other techniques. A therapeutic regimen may include a prescribed dosage of one or more therapeutic agents. [64] The term “therapeutic agent” refers to any drug, agent, biologically active agent, biological substance, chemical substance or biochemical substance that is capable of being administered in a therapeutically effective amount to a subject. In various aspects and embodiments of the disclosure therapeutic agents can include one or more compounds disclosed herein. [65] The term “therapeutically effective amount” refers to an amount of a therapeutic agent, compound, formulation, material, or composition, as described herein effective to achieve a particular biological result. Such results may include, but are not limited to, the inhibition of a disease as determined by any means suitable in the art. [66] An effective regime refers to a combination of an amount, frequency of administration and route of administration effective to treat a condition. Effective treatment delays onset of, reduces, inhibits deterioration of, or ameliorates at least one sign or symptom of the condition. A regime can be considered effective by demonstrating a statistically significant delay, reduction, inhibition, or amelioration (p ≤ 0.05) in a sign or symptom comparing a population of treated human subjects (or animal models) having or at risk of the condition being treated relative to a control population of subjects (or animal models) with the condition who are not treated with the agent. The control population can be contemporaneously treated with a placebo or can be a historical control. A treatment can alternatively or additionally be considered effective if it reduces or ameliorates at least one sign or symptom of the condition in a treated subject relative to the same subject before treatment. [67] Unless otherwise apparent from the context, reference to a particular drug, e.g., by its international non-proprietary name, should be understood as encompassing the drug in the exact form associated with the name as well as minor variations in which the active moiety is supplied as free acid or free base instead of pharmaceutically acceptable salt or vice versa, or is supplied as different pharmaceutically acceptable salt or is supplied as an amide or ester of the active
moiety, such variations being in pharmaceutically acceptable form and with insubstantial, if any, variation in activity. Methods and Therapeutic agents [68] In one aspect, the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (I):
or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: R1 is H, or C1-4 alkyl; Q is a bond, or C1-4 alkyl; A is aryl, heteroaryl optionally substituted with 0-3 substituents independently chosen from halogen, C1-4 alkyl, CH2F, CHF2, CF3, CN, aryl, hetaryl, OCF3, OC1-4alkyl, OC2- 5alkylNR4R5, Oaryl, Ohetaryl, CO2R4, CONR4R5, nitro, NR4R5, C1-4 alkylNR4R5, NR6C1-
R4, R5 are each independently H, C1-4 alkyl, C1-4 alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, aryl, hetaryl, C1-4alkyl aryl, C1-4 alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR7; R6 is selected from H, C1-4 alkyl; R7 is selected from H, C1-4 alkyl, aryl, hetaryl, C1-4alkyl aryl, C1-4 alkyl hetaryl; R2 is 0-2 substituents independently selected from halogen, C1-4alkyl, OH, OC1-4alkyl, CH2F, CHF2, CF3, OCF3, CN, C1-4alkylNR8R9, OC1-4alkylNR8R9, CO2R8, CONR8R9, NR8R9, NR8COR9, NR10CONR8R9, NR8SO2R9;
R8, R9 are each independently H, C1-4 alkyl, C1-4 alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, aryl, hetaryl, C1-4 alkyl aryl, C1-4 alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR11; R10 is selected from H, C1-4 alkyl, aryl or hetaryl; R11 is selected from H, C1-4 alkyl, aryl, hetaryl, C1-4alkyl aryl, C1-4 alkyl hetaryl; Y is halogen, OH, NR12R13, NR14COR12, NR14CONR12R13, N14SO2R13; R12 and R13 are each independently H, CH2F, CHF2, CF3, CN, C1-4 alkyl optionally substituted with OH, OC1-4alkyl or NR15 R16 , cycloalkyl; cyclohetalkyl, C1-4 alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, or may be joined to form an optionally substituted 3-6 membered ring optionally containing an atom selected from O, S, NR14; R14, R15 and R16 are each independently selected from H, C1-4 alkyl; n=0-4; W is selected from H, C1-4alkyl, C2-6alkenyl; where C1-4alkyl or C2-6alkenyl may be optionally substituted with C1-4alkyl, OH, OC1-4alkyl, NR15R16; R15, and R16 are each independently H, C1-4 alkyl, C1-4alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR17; R17 is selected from H, C1-4 alkyl. [69] In another aspect disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (II):
or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: R1 is H, C1-4 alkyl; Q is a bond, or C1-4 alkyl; A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C1-4 alkyl, CH2F, CHF2, CF3, CN, aryl, hetaryl, OCF3, OC1-4alkyl, OC2- 5alkylNR4R5, Oaryl, Ohetaryl, CO2R4, CONR4R5, nitro, NR4R5, C1-4 alkylN R4R5, NR6C1-4alkylN R4R5, NR4COR5, NR6CON R4R5, NR4SO2R5; R4, R5 are each independently H, C1-4 alkyl, C1-4 alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, aryl, hetaryl, C1-4alkyl aryl, C1-4 alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR7; R6 is selected from H, C1-4 alkyl; R7 is selected from H, C1-4 alkyl, aryl, hetaryl, C1-4alkyl aryl, C1-4 alkyl hetaryl; R2 is 0-2 substituents independently selected from C1-4alkyl and OC1-4alkyl; Y is CH2OH, OC1-4alkylOH, OC1-4alkylR12, OC1-4alkylNR12NR13, C(O)R12 , CH2R12, COOR12, CONR12R13, OCON R12R13, CH2N R12R13, NHCOR12, NHCON R12R13, R12 and R13 are each independently H, C1-2 alkyl, (CH2)3NEt2, (CH2)2NMe2, (CH2)5NH2, (CH2)2OH,
n=0-4;
W is selected from H, C1-4alkyl, C2-6alkenyl; where C1-4alkyl or C2-6alkenyl may be optionally substituted with C1-4alkyl, OH, OC1-4alkyl, NR15R16; R15, and R16 are each independently H, C1-4 alkyl, C1-4alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR17 R17 is selected from H, C1-4 alkyl; and wherein when Y is CH2R12 then R12 is not H, C1-2alkyl. [70] In another aspect, the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (III):
or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: X1, X2, X3, X4 are selected from the following: (i) X1 and X2 are N and X3 and X4 are C independently substituted with Y; (ii) X1 and X4 are N and X2 and X3 are C independently substituted with Y; (iii) X1 and X3 are N and X2 and X4 are C independently substituted with Y; (iv) X2 and X4 are N and X1 and X3 are C independently substituted with Y; (v) X1 is N and X2, X3, and X4 are C independently substituted with Y; (vi) X3 is N and X1, X2, and X4 are C independently substituted with Y; (vii) X4 is N and X1, X2, and X3 are C independently substituted with Y; (viii) X2 is N and X1, X3, and X4 are C independently substituted with Y; and (ix) X1, X2 and X3 are N and X4 is C substituted with Y; R1 is H, C1-6alkyl, C1-6alkylNR5R6, C1-6alkylNR5COR6, C1-6alkylNR5SO2R6, C1-6alkylCO2R5, C1-6alkylCONR5R6;
R5 and R6 are each independently H, C1-4alkyl, aryl, hetaryl, C1-4alkylaryl, C1- 4alkylhetaryl or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR7; R7 is selected from H, C1-4alkyl; R2 is selected from C1-6alkylOH, OC2-6alkylOH, C1-6alkylNR8R9, OC2-6alkylN R8R9, C1- 6alkylNR8COR9, OC2-6alkylNR8COR9, C1-6alkylhetaryl, OC2-6alkylhetaryl, OCON R8R9, NR8COOR9, NR10CONR8R9, CONR8R9, NR8COR12; R8, R9 are each independently H, C1-4alkyl, C1-4alkylNR11R13, hetaryl, cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR14; R12 is C2-4alkyl, C1-4alkylNR11R13, hetaryl, cyclohetalkyl; R11, R13 are each independently H, C1-4alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR14; R14 is selected from H, C1-4alkyl; R10 is H, C1-4 alkyl; R3 and R4 are each independently H, halogen, C1-4alkyl, OH, OC1-4alkyl, CF3, OCF3; Q is a bond, or C1-4 alkyl; W is selected from H, C1-4alkyl, C2-6alkenyl; where C1-4alkyl or C2-6alkenyl may be optionally substituted with C1-4alkyl, OH, OC1-4alkyl, NR15R16; R15 and R16 are each independently H, C1-4alkyl, C1-4alkyl cycloalkyl, C1-4alkyl cyclohetalkyl, aryl, hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR17; R17 is selected from H, C1-4alkyl; A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C1-4 alkyl, CF3, aryl, hetaryl, OCF3, OC1-4alkyl, OC2-5alkylNR18R19, Oaryl, Ohetaryl, CO2R18, CONR18R19, NR18R19, C1-4 alkylNR18R19, NR20C1-4alkylNR18R19, NR18COR19, NR20CONR18R19, NR18 SO2R19; R18, R19 are each independently H, C1-4 alkyl, C1-4 alkyl cyclohetalkyl, aryl, hetaryl, C1- 4alkyl aryl, C1-4 alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21;
R21 is selected from H, C1-4alkyl; R20 is selected from H, C1-4alkyl; Y is selected from H, C1-4alkyl, OH, NR22R23; and R22, R23 are each independently H, C1-4alkyl. [71] In another aspect, the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (IV):
or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: X1, X2, X3, X4 are selected from the following: (i) X1 and X2 are N and X3 and X4 are C independently substituted with Y; (ii) X1 and X4 are N and X2 and X3 are C independently substituted with Y; (iii) X1 and X3 are N and X2 and X4 are C independently substituted with Y; (iv) X2 and X4 are N and X1 and X3 are C independently substituted with Y; (v) X1 is N and X2, X3, and X4 are C independently substituted with Y; (vi) X3 is N and X1, X2, and X4 are C independently substituted with Y; (vii) X4 is N and X1, X2, and X3 are C independently substituted with Y; (viii) X2 is N and X1, X3, and X4 are C independently substituted with Y; and (ix) X1, X2 and X3 are N and X4 is C substituted with Y; R1 is H, C1-6alkyl, C1-6alkylNR5R6, where R5 and R6 are each independently H, C1-4alkyl, aryl, hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR7; R7 is selected from H, C1-4alkyl;
R2 is selected from C1-6alkylOH, OC2-6alkyl OH, C1-6alkylNR8R9, OC2-6alkyl NR8R9, C1- 6alkylNR8COR9, OC2-6alkylNR8COR9, C1-6alkylhetaryl, OC2-6alkylhetaryl, OCONR8R9, NR8COOR9, NR10CONR8R9, CONR8R9, NR8COR12; R8, R9 are each independently H, C1-4alkyl, C1-4alkylNR11R13, hetaryl, cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR14; R12 is C2-4alkyl, C1-4alkylNR11R13, hetaryl, cyclohetalkyl; R11, R13 are each independently H, C1-4alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR14; R14 is selected from H, C1-4alkyl; R10 is H, C1-4alkyl; R3 and R4 are each independently H, halogen, C1-4alkyl, OH, OC1-4alkyl, CF3, OCF3; Q is CH; W is selected from C1-4alkyl, C2-6alkenyl; where C1-4alkyl or C2-6alkenyl may be optionally substituted with C1-4alkyl, OH, OC1-4alkyl, NR15R16; R15, and R16 are each independently H, C1-4alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR17; R17 is selected from H, C1-4alkyl; A is aryl, hetaryl optionally substituted with 0-2 substituents independently chosen from halogen, C1-4alkyl, CF3, aryl, hetaryl, OCF3, OC1-4alkyl; OC2-3alkylNR18R19, Oaryl, Ohetaryl, CO2R18, CONR18R19, NR18R19, C1-4alkylNR18R19, NR20C1-4alkylNR18R19, NR18COR19, NR20CONR18R19, NR18SO2R19; R18, R19 are each independently H, C1-4alkyl, C1-4alkyl cyclohetalkyl, aryl, hetaryl, C1- 4alkyl aryl, C1-4alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21; R21 is selected from H, C1-4alkyl; R20 is selected from H, C1-4alkyl; Y is selected from H, C1-4alkyl, NR22R23; R22, R23 are each independently H, C1-4alkyl.
[72] In another aspect, the disclosure provides a method of treating HCC comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (V):
or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: X1, X2, X3, X4 are selected from the following: (i) X1 and X2 are N and X3 and X4 are C independently substituted with Y; (ii) X1 and X4 are N and X2 and X3 are C independently substituted with Y; (iii) X2 and X4 are N and X1 and X3 are C independently substituted with Y; (iv) X1 is N and X2, X3, and X4 are C independently substituted with Y; (v) X3 is N and X1, X2, and X4 are C independently substituted with Y; (vi) X4 is N and X1, X2, and X3 are C independently substituted with Y; (vii) X2 is N and X1, X3, and X4 are C independently substituted with Y; and (viii) X1, X2 and X3 are N and X4 is C substituted with Y; R1 is H, C1-6alkyl, C1-6 alkylNR5R6, C1-6alkylNR5COR6, C1-6alkylNR5SO2R6, C1-6alkylCO2R5, C1-6alkylCONR5R6; R5 and R6 are each independently H, C1-4alkyl, aryl, hetaryl, C1-4alkylaryl, C1- 4alkylhetaryl or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR7; R7 is selected from H, C1-4alkyl; R2 is selected from OH, OC1-6alkyl, C1-6alkylOH, OC2-6alkylOH, C1-6alkylNR8R9, OC2- 6alkylNR8R9, C1-6alkylNR8COR9, OC2-6alkylNR8COR9, C1-6alkylhetaryl, OC2- 6alkylhetaryl, OCONR8R9, NR8COOR9, NR10CONR8R9, CONR8R9, NR8COR12;
R8, R9 are each independently H, C1-4alkyl, C1-4alkylNR11R13, hetaryl, cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR14; R12 is C2-4alkyl, C1-4alkylNR11R13, hetaryl, cyclohetalkyl; R11, R13 are each independently H, C1-4alkyl, or may be joined to form an optionally substituted 3-8membered ring optionally containing an atom selected from O, S, NR14; R14 is selected from H, C1-4alkyl; R10 is H, C1-4 alkyl; R3 and R4 are each independently H, halogen, C1-4alkyl, OH, OC1-4alkyl, CF3, OCF3; Q is a bond, or C1-4alkyl; W is selected from H, C1-4alkyl, C2-6alkenyl; where C1-4alkyl or C2-6alkenyl may be optionally substituted with C1-4alkyl, OH, OC1-4alkyl, NR15R16; R15, and R16 are each independently H, C1-4alkyl, C1-4alkyl cycloalkyl, C1-4alkyl cyclohetalkyl, aryl, hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR17; R17 is selected from H, C1-4alkyl; A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C1-4 alkyl, CF3, aryl, hetaryl, OCF3, OC1-4alkyl, OC2-5alkylNR18R19, Oaryl, Ohetaryl, CO2R18, CONR18R19, NR18R19, C1-4 alkylNR18R19, NR20C1-4alkylNR18R19, NR18COR19, NR20CONR18R19, NR18SO2R19; R18, R19 are each independently H, C1-4 alkyl, C1-4 alkyl cyclohetalkyl, aryl, hetaryl, C1- 4alkyl aryl, C1-4 alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21; R21 is selected from H, C1-4 alkyl; R20 is selected from H, C1-4 alkyl; Y is selected from H, C1-4alkyl, OH, NR22R23; R22, R23 are each independently H, C1-4 alkyl. [73] In yet a further aspect, the disclosure provides a method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (VI):
or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: R’1 is C1-4 alkyl, R’2 is independently selected from the group consisting of: OH, NHCOR’12, and NHCONHR’12; R’12 is independently selected from the group consisting of H, C1-4 alkyl optionally substituted with OH, OC1-4alkyl or NR’15R’16; R’15 and R’16 are each independently selected from H and C1-4 alkyl; X’1, X’2, X’3, X’4 are selected from the following: (i) X’1 and X’2 are N and X’3 and X’4 are C independently substituted with Y’; (ii) X’1 and X’4 are N and X’2 and X’3 are C independently substituted with Y’; (iii) X’1 and X’3 are N and X’2 and X’4 are C independently substituted with Y’; (iv) X’2 and X’4 are N and X’1 and X’3 are C independently substituted with Y’; Y’ is selected from H, OH, C1-4alkyl, and OC1-4alkyl; X’5 is selected from N and C, and when X’5 is C, R’6 is selected from the group H, halogen, C1-4 alkyl, OC1-4alkyl, CF3, and OCF3: R’5 is selected from the group C1-4 alkyl, OC1-4alkyl, CF3, and OCF3; R’7 is selected from the group H, halogen, C1-4 alkyl, OC1-4alkyl, CF3, and OCF3. [74] In the above described aspects it should be noted that: C1-4alkyl means an unsubstituted or optionally substituted straight or branched alkyl chain; Aryl means unsubstituted or optionally substituted phenyl or naphthyl; Hetaryl means an unsubstituted or optionally substituted 5- or 6-membered heteroaromatic ring containing one or more heteroatoms selected
from O, N, S; Cycloalkyl means a 3-8 membered saturated ring; and Cyclohetalkyl means an optionally substituted 3-8 membered saturated ring containing 1-3 heteroatoms selected from O, S, NR24, where R24 is H, C1-4alkyl, aryl, hetaryl. [75] In some embodiments, the method comprises administering to a subject in need of treatment an amount of at least one compound of the general formula (VI) selected from the group consisting of:
[76] In some further embodiments, the methods comprise administering a compound of the structure:
(TXR-311, or compound 24). [77] Compound 24, or (S)-1-ethyl-3-(2-methoxy-4-(5-methyl-4-((1-(pyridin-3- yl)butyl)amino)pyrimidin-2-yl)phenyl)urea, is also identified as CYT997 (Lexibulin), a microtubule targeting agent reported previously in Bioorg Med Chem Lett 19:4639–4642, 2009; Mol Cancer Ther 8:3036–3045, 2009. [78] In the some of the above aspects and embodiments discussed above, the methods treat a subject who has HCC. Use of the Compounds for Treatment of Liver Cancer [79] In some aspects and embodiments the disclosure provides for the use of the compounds disclosed herein for the treatment of liver cancer. Thus, in one aspect, the disclosure relates to the use of compounds of general formula (I) in the treatment of liver cancer. In another aspect, the disclosure relates to the use of compounds of general formula (II) in the treatment of liver cancer. In another aspect, the disclosure relates to the use of compounds of general formula (III) in the treatment of liver cancer. In yet another aspect, the disclosure relates to the use of compounds of general formula (IV) in the treatment of liver cancer. In another aspect, the disclosure relates to the use of compounds of general formula (V) in the treatment of liver cancer. In another aspect, the disclosure relates to the use of compounds of general formula (VI)
in the treatment of liver cancer. In some embodiments of the aspects relating to the use of the compounds for treating liver cancer, the compound may be selected from any of compounds (1)- (24). In further embodiments, the disclosure relates to the use of compound 24 for the treatment of liver cancer. In certain of the above aspects and embodiments relating to the use of compounds, the use relates to the treatment of HCC. In further embodiments, the disclosure provides for the use of compound 24 in the treatment of HCC. Patients and Subjects Amenable to Treatment [80] In certain embodiments, the methods disclosed above relate to the treatment of a mammalian subject and preferably relate to methods for treating a human patient who has liver cancer. No single system is available that could be called the “standard” for classifying a liver cancer such as, for example, HCC. Like with any cancer, the goals of a tumor staging system in HCC are to estimate a patient’s prognosis, which allows for appropriate therapy to be selected. The identification of that appropriate therapy, in turn, requires a staging paradigm that standardizes the platform for researchers to exchange data regarding treatments and outcomes. Currently, seven HCC staging systems with respect to their development and limitations are commonly utilized. These staging systems include TNM, Okuda staging, BCLC staging classification, Child-Pugh score, Japan integrated staging, Chinese University Prognostic Index (CUPI), and the French scoring system (GRETCH). (See, e.g., Subramaniam et al., Chin Clin Oncol (2013) 2(4):33.) [81] The Okuda system is a prognostic score introduced in 1985 and incorporates both tumor features as well as the degree of underlying cirrhosis. Using a cohort of 850 patients with an unequivocal diagnosis of HCC between 1975-1983, Okuda and colleagues devised a staging system based on four factors representing advanced disease. This includes tumor occupying greater or less than 50% of the liver, the presence or absence of ascites, and serum albumin and bilirubin levels (Table 1). In the original cohort, median survival was 11.5 months for Stage I, 3.0 months for Stage II and 0.9 months for Stage III. (See, e.g., Subramaniam et al., Chin Clin Oncol (2013) 2(4):33.) [82] The Child-Pugh score is a scoring system to measure the severity of chronic liver disease inclusive of cirrhosis. The intention is to provide a system with which clinicians can
objectively communicate about liver function. (See, e.g., Subramaniam et al., Chin Clin Oncol (2013) 2(4):33.) Table 1. Okuda staging
[83] Among the above seven staging systems, BCLC is used by many practitioners to guide clinical decision-making, because of its widespread presence in contemporary HCC research. The BCLC classification was first published in 1999 and is considered the standard HCC system by the American Association of for the Study of Liver Disease (AASLD) and European Association for the Study of the Liver. (See, e.g., Subramaniam et al., Chin Clin Oncol (2013) 2(4):33.) [84] Derived from a single institution experience, BCLC takes into account size and extent of the primary tumor, liver function and physiological factors and incorporates the Okuda stage and Child-Pugh score (Table 2). There is a corresponding treatment schedule for each stage (Table 3), ranging from curative therapies such as resection or transplant for early stage patients to best supportive care for end-stage patients. (See, e.g., Subramaniam et al., Chin Clin Oncol (2013) 2(4):33.) Table 2. Barcelona Clinic Liver Cancer (BCLC) staging classification
Table 3. Treatment schedule proposed for hepatocellular carcinoma (HCC) cirrhotic patients according to the BCLC classification system
[85] Signs and symptoms of HCC may include: • Pain in the upper right part of your belly • A lump or feeling of heaviness in your upper belly • Bloating or swelling in your belly • Loss of appetite and feelings of fullness • Weight loss • Weakness or deep fatigue
• Nausea and vomiting • Yellow skin and eyes • Pale, chalky bowel movements and dark urine • Fever [86] Although the mainstay of therapy for HCC is surgical resection, the majority of patients are not eligible because of tumor extent or underlying liver dysfunction. Several other treatment modalities are available, including:1) liver transplantation; 2) radiofrequency ablation (RFA) and microwave ablation; and 3) percutaneous ethanol or acetic acid ablation. [87] The most commonly offered therapy is transcatheter arterial chemoembolization (TACE). TACE is performed by an interventional radiologist who selectively cannulates the feeding artery to the tumor and delivers high local doses of chemotherapy, including doxorubicin, cisplatin, or mitomycin C. To prevent systemic toxicity, the feeding artery is occluded with gel foam or coils to prevent flow. Because most hepatocellular carcinomas derive 80-85% of their blood flow from the hepatic artery, the therapy can be well targeted, leaving the normal parenchyma, which is primarily supplied by portal blood, minimally affected. A reduction in tumor burden can be achieved in 16-61% of treated patients. [88] Subjects amenable to treatment include subjects having a diagnosis of probable or possible hepatocellular carcinoma, or who do not yet meet such criteria but have sufficient sign(s), symptom(s), or genetic risk factor(s) of hepatocellular carcinoma as to place them at a statistically significant risk of developing hepatocellular carcinoma relative to the general population. Treatment [89] In subjects already exhibiting a sign(s) and/or symptom(s) of liver cancer such as HCC, for example, administration of the compounds, compositions, and formulations disclosed herein can reverse, halt, or delay progression of disease (e.g., HCC) and/or reduce the severity of the clinical sign(s) or symptom(s) associated with liver cancer such as HCC. [90] Some subjects are asymptomatic, but have one or more risk factors or may be at an early stage of the condition(s). In such subjects, administration of the compounds disclosed herein can inhibit or delay onset or progression of a condition to later stage and/or reduce the severity of the condition, once present.
Formulations and Administration of Therapeutic Agents [91] The methods may include administration of the compounds at a dosage level that is appropriate based on a number of factors, including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the subject undergoing therapy. Dosages may generally be in a range of about 0.01 to about 500 mg per kg patient body weight per day which can be administered in single or multiple doses. In embodiments, the dosage level can range from about 0.1 to about 250 mg/kg per day; or from about 0.5 to about 100 mg/kg per day; or from about 0.1 to about 50 mg/kg per day. One of ordinary skill will appreciate that within these ranges the dosage may be about 0.05 to 0.5, about 0.5 to 5, or about 5 to 50 mg/kg per day. [92] The methods can include any route of administration. For example, when administered orally, the compounds or compositions can be provided in the form of tablets containing 1.0 to 1000 milligrams of the active ingredient, (e.g., 1.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of the active ingredient) for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 4 times per day (e.g., including twice or three times per day). [93] The compounds used in the methods herein may be administered by any suitable route, for example, orally, such as in the form of tablets, capsules, granules, suspensions, or powders; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intracisternal injection or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents. The compounds may, for example, be administered in a form suitable for immediate release or extended release as is generally known in the art. Combination Therapies [94] As discussed above, the methods disclosed herein can be used as a monotherapy for treatment or prophylaxis of liver cancer (e.g., HCC). In some embodiments of the above aspects,
the disclosed methods of treatment can be used in combination with one or more additional therapeutic interventions. Non-limiting examples include radiation, surgery, immunotherapy, and other anti-cancer (i.e., anti-neoplastic) agents. In some embodiments, the methods further comprise administration of the compounds disclosed above in combination with an additional anti-cancer agent that may be selected from the non-limiting examples of alkylating agents, antimetabolites, natural antineoplastic agents, hormonal antineoplastic agents, angiogenesis inhibitors, differentiating reagents, RNA inhibitors, antibodies or immunotherapeutic agents, gene therapy agents, small molecule enzymatic inhibitors, biological response modifiers, and anti-metastatic agents. In non-limiting embodiments, a combination therapy can include sorafenib, which represents the current standard of care. Synthesis of Compounds [95] The compounds described herein can be obtained through commercial sources or prepared using synthetic methods known in the art. Non-limiting examples for compound synthesis are disclosed in U.S. Patent 7,981,900 which refers to a 2-step synthetic process starting from a dihaloheterocycle. [96] Briefly, the first step is a nucleophilic aromatic substitution to generate a monoamino- monohalo intermediate. The nucleophilic aromatic substitution can be carried out by addition of a primary or secondary amine to the di-halogenated heterocycle in an organic solvent (e.g., alcohols, aliphatic and cyclic ethers, ethanol, DMF, toluene, or xylene). The reaction is typically performed at elevated temperature in the presence of excess amine or a non-nucleophilic base such as triethylamine or diisopropylethylamine, or an inorganic base such as potassium carbonate or sodium carbonate. [97] Alternatively, the amino substituent may be introduced through a transition metal catalyzed amination reaction, using catalysts such as Pd(OAc)2/P(t-Bu)3, Pd2(dba)3/BINAP and Pd(OAc)2/BINAP. These reactions are typically carried out in solvents such as toluene or dioxane, in the presence of bases such as cesium carbonate or sodium or potassium tert-butoxide at temperatures ranging from room temperature to reflux. [98] The amines employed in the first step of the synthesis of these compounds are obtained commercially or are prepared using methods well known to those skilled in the art (e.g., α-alkylbenzylamines prepared through reduction of oximes using reductants known in the art).
The α-alkylbenzylamines may also be prepared using known methods, such as for example reductive amination of ketones (e.g., the Leuckart-Wallach reaction) or from α-alkylbenzyl alcohols. Further, methods for chiral reduction are known in the art. [99] The second step of the synthesis involves cross-coupling of the monoamino- monohalo intermediate with a functionalized coupling reagent, typically using palladium. Typical coupling reagents can include those used in Suzuki coupling (boronic acids or esters, see e.g., Miyaura, N. and Suzuki, Chem. Rev. 1995, 952457); Stille coupling (tin hydrides, see e.g., Stifle, J. K., Angew. Chem., Int. Ed. Engl., 1986, 25, 508), Kumada coupling (Grignard reagents, see e.g., Kumada, M.; Tamao, K.; Sumitani, K. Org. Synth.1988, Coll. Vol. 6, 407.), or Negishi coupling (organo-zinc species, see e.g., Negishi, E.; J. Organomet. Chem. 2002, 653, 34) each incorporated by reference. For example, Suzuki coupling may be performed in an organic solvent in the presence of an inorganic base at elevated temperatures, and using palladium catalyst known in the art. [100] Derivative compounds may be prepared from the compounds formed by above reactions using techniques known in the art. The synthetic steps above can be modified as to start with the palladium mediated cross-coupling reaction to furnish a mono-halo heterocyclic species. Amine displacement of the halo substituent can then be performed as described above. [101] The following Examples provide an illustration of some of the aspects and embodiments described above, and are not intended to limit the scope of the claimed invention. EXAMPLES Example 1: Identifying candidate compounds using in vitro cytotoxicity assays in human hepatocellular carcinoma cells and primary human hepatocytes [102] A set of structurally diverse candidate compounds were identified for investigation based on existing available information using a process that combines an initial computational- based analysis and review of existing information available for candidate compounds with additional research and development of the identified candidate compounds specifically directed to determine the efficacy of the compounds in the treatment of liver cancer. To screen the candidate compounds, five human HCC cell lines were used in a cell proliferation assay study: HepG2, Hep3B, Hep40, Huh7 and PLC/PRF/5 (PLC5). All cell lines were obtained from either the American Type Culture Collection (ATCC; Manassas, VA) or provided as a gift. Cells were
maintained in Dulbecco’s Modified Eagle’s Medium, 10% fetal calf serum and penicillin/streptomycin. Cells were cultured at 37°C in a humidified atmosphere with 5% CO2. [103] A stock solution (10 mM in DMSO, 100%) was prepared for each screened candidate compound. Cells were seeded at 5000 cells per well in 96-well plates and allowed to adhere overnight. Compounds were then added at the desired final concentrations, and incubated for an additional 72 hours before cell proliferation was assessed. [104] Liver cytotoxicity was assessed using three primary human hepatocytes: HU1767, HU8216, and HU8264 (purchased from ThermoFisher Scientific (Waltham, MA)) for candidate compounds identified from the HCC cell line assay, the compounds identified as TXR-311 (also identified as Compound 24 herein) and TXR-312. Cryopreserved hepatocytes were thawed using cryopreserved hepatocytes recovery medium. These cells were plated in 96-well plates and maintained in Williams’ Medium E and supplemented with hepatocyte maintenance supplement hPack (serum-free). Cells were cultured at 37°C in a humidified atmosphere with 5% CO2. [105] For the hepatocyte toxicity assay, a stock solution of (10 mM in 100% DMSO) was prepared for the selected candidate compounds. Cells were seeded at 30,000 cells per well in 96- well plates and allowed to adhere overnight. Compounds were then added at the desired final concentrations, and incubated for an additional 72 hours before cell proliferation was assessed. [106] Two methods were used for the calculation of IC50: cell proliferation and cell viability assays. Both assays were performed using the respective commercial kits and in accordance with manufacturer’s protocol (CellTiter 96® AQueous One Solution Cell Proliferation kit and CellTiter-Glo® Luminescent Cell Viability Assay; (Promega; Madison, Wisconsin). The IC50 was calculated based on an estimate of the anti-proliferative and cytotoxic effects observed in the cell proliferation and cell viability assays, respectively. [107] Results. [108] HCC toxicity. Two of the screened candidate compounds in the HCC cytotoxicity assay were selected for evaluation in the hepatocyte toxicity assays based on calculated IC50 values (0.044 ± 0.019 µM; and 5.5 ± 1.53 µM). Data for the two selected compounds, TXR-311 and TXR-312, were obtained in triplicate for each cell line at each concentration. The mean IC50 for each selected compound and for each cell line was calculated and presented in Tables 4 and 5. The mean IC50 for each selected compound was calculated and presented in Table 6 and plotted in Figures 1A-1E.
[109] Hepatocyte toxicity. The cytotoxicity of each selected compound was tested in primary human hepatocytes. The results are summarized in Table 7 and plotted in Figure 2. One of the selected compounds, TXR-311, had a significantly higher IC50 (~540 fold) observed in hepatocytes compared to the IC50 in HCC cell lines (23.62 ± 5.9 µM compared to 0.044 ± 0.018 µM, respectively), indicating that its activity has a high selectivity for HCC tumor cells with very low toxicity to normal liver cells. There is no previously existing data that would have predicted these findings, and in view of this data, the TXR-311 compound was chosen for further characterization in in vivo studies. Example 2: Maximum tolerated dose (MTD) study in BALB/c mice [110] Twenty female/male BALB/c mice of approximately 8-10 weeks of age and weighing 26-29 grams each at the time of dosing were used in a dose range-finding study. Animals were acclimated for 5 days prior to dose administration. The animals were group-housed in sterilized plastic “shoebox” cages with microisolator caps in a single room dedicated to rodents. LabDiet® 5001 Rodent Diet (Purina Mills, Inc.; St. Louis, MO) or other approved diets were provided ad libitum throughout the acclimation and treatment phases. Fresh tap water was provided ad libitum to the animals via water bottles. Twelve hours of light and twelve hours of dark was provided in the animal rooms. [111] The study (summarized in Table 8) was conducted to provide data relating to a maximum tolerated level of the compound TXR-311 in BALB/c mice following 42 days of tri- weekly dosing. The study included three groups with up to five female or male mice in each group. Starting on Day 0 and continuing to Day 41, animals in Groups 2-4 were dosed tri-weekly (Q3W) via oral gavage (PO) with the compound TXR-311 at 20, 40 and 60 mg/kg, respectively (Table 1). Measurements were recorded throughout the in-life phase, including: clinical observations, at least once daily (QD); body weight, tri-weekly. Animals were sacrificed on day 42, one day after administration of the final dose and a final body weight recorded. Table 8. Summary of MTD Study Design
[112] The survival curve of the dose range-finding study is presented in Figure 3. A total of 7 unscheduled mortalities were observed, all of which occurred in groups 3 and 4 (Table 9). In group 4 treated with 60 mg/kg of TXR-311, animals exhibited severe diarrhea and signs of dehydration by Day 5. Three animals in this group were found dead on Day 6 and 2 animals were found dead on Day 7. In group 3 treated with 40 mg/kg of TXR-311, animals exhibited signs of dehydration on Day 14. In this group one mouse was found dead on Day 16 and a second mouse was found dead on Day 20. On Day 21, due to the observed toxicity, the animals were removed from study. In group 2 treated with 20 mg/kg of TXR-311, there were no unscheduled mortalities during the in-life period. [113] Body weight data are provided in Table 10 and plotted in Figure 4. Animals treated with 60 mg/kg of TXR-311 died prior to Day 7, the first body weight measurement, thus no data are presented. Starting on Day 7 animals treated with 40 mg/kg of TXR-311 exhibited a decrease in body weight. By Day 14, these animals showed a 16% decrease in body weight when compared to their pre-dose weight. Animals treated with 20 mg/kg of TXR-311 and vehicle exhibited a gain in body weight. These results indicate that treating mice three times weekly with 20 mg/kg of TXR-311 is safe and well tolerated. Table 9. Summary of Unscheduled Mortalities
Table 1. MTD study - Summary of Body Weight
Example 3: Tumor inhibition activity in NSG mice with HCC patient-derived tumor xenografts [114] Female/male NSG mice (NOD scid gamma, NOD-scid IL2Rgnull, NOD- scid IL2Rgammanull) of approximately 8-10 weeks of age and weighing 27-33 g each at the time of dosing were obtained to establish two patient-derived xenograft (PDX) orthotopic tumor models. The animals were group housed (n ≤ 5) in sterilized plastic “shoebox” cages with microisolator caps in a single room dedicated to immunocompromised rodents. Sterile LabDiet® 5062 PicoVac® Rodent Diet 20 (Purina Mills, Inc.; St. Louis, MO) or other approved sterilized diets was provided ad libitum throughout the acclimation and in-life phases. Autoclave-sterilized tap water from the Palo Alto Municipal Water Supply was provided ad libitum to the animals via water bottles or a modified rack-watering system. Twelve hours of light and twelve hours of dark was provided in the animal rooms. [115] Two studies were performed with different patient-derived xenograft tumors: PDX1 and PDX2. PDX1 and PDX2 were established from HCC patients who underwent surgical resection for their HCC tumors. PDX1 was derived from a patient with non-viral HCC with cirrhosis and metastasis to intra-abdominal lymph nodes. The tumor was diagnosed as a moderately-differentiated HCC, stage 1. PDX2 was derived from a patient with HBV-associated HCC, with cirrhosis and vascular invasion. The tumor was diagnosed as being poorly- differentiated HCC, stage 2. Both patients gave informed consent to have their tissue specimens used for research studies. In mice, PDX1 typically has a faster growth rate (about double) compared to PDX2. There are no known genetic mutations for each PDX tumor. [116] The PDX1 study was performed in 18 tumor-bearing NSG mice, consisting of two groups of nine mice per group. The PDX2 study was performed in 20 tumor-bearing NSG mice, consisting of two groups of seven mice per group and one group of six mice. Both PDX1 and PDX2 cells were labeled with the luciferase reporter gene using a lenti-virus expression vector. Approximately one month before the projected start of each of the PDX studies, two mice from each PDX cohort were implanted with tumor cells. Implantation was performed via
subcutaneous (SC) injection into the cephalad dorsum area with 0.1 mL (~5 x 106 cells) per mouse. The tumors cells were administered as a single-cell suspension of each of the PDX cells suspended in 50% Matrigel (BD Biosciences; Bedford, MA) in phosphate-buffered saline (PBS). Following implantation, mice were returned to their cages and tumors were allowed to develop, for up to 28-42 days, depending on the growth rate of the tumors. Tumor growth was monitored once weekly using Xenogen IVIS in vivo imaging system. Luciferase images were acquired following intraperitoneal injection (IP) of D-luciferin substrate. [117] Donor animals were sacrificed once tumors had reached the desired diameter of ~100 mm. The tumor was then removed and dissected into ~2 mm3 fragments and surgically implanted into the left lobe of the liver in NSG mice. Starting on Day 0 (7 days after tumor implantation) and for a total of up to 42 consecutive days. The in-life study performed as two cohorts as shown in Table 11. In the first cohort, animals implanted with PDX1 were dosed tri- weekly (Q3W) with TXR-311 or vehicle. In the second cohort, animals implanted with PDX2 were dosed tri-weekly (Q3W) with TXR-311 or vehicle and 5 times a week with sorafenib. All mice were dosed via oral gavage (PO) at 5 mL/kg with vehicle, TXR-311, (both on M/W/F each week) or sorafenib (on M/T/W/Th/F each week) as specified in Table 11. Throughout the in-life phase, the following measurements were recorded: tumor growth once weekly using Xenogen IVIS in vivo imaging system; body weight, once weekly (Q1W). Luciferase images were acquired following intraperitoneal injection (IP) of D-luciferin substrate. Sedated animals were placed in the imaging chamber and the image was taken 10 mins after IP injection of D-luciferin substrate. [118] Animals in the PDX1 study were sacrificed on Day 25 due to excessive tumor growth and significant body weight loss (>18%) observed in both vehicle and drug-treated (TXR-311) groups. No unscheduled mortality was observed in the PDX1 or PDX2 studies. Animals in the PDX2 study were sacrificed on Day 42. During necropsy of both cohorts, the liver was removed, and the xenograft tumor was excised, measured and placed in formalin for future analysis. [119] The study design is summarized in Table 11. The PDX1 study consisted of two groups of nine tumor-harboring mice each, and the PDX2 study consisted of 2 groups of seven and one group of 6 tumor-harboring mice.
Table 11. Summary of Study Design for PDX1 and PDX2 dy weight cropsy, removal of er and measurement xenograf
[120] Results [121] PDX1 study: Tumor size was monitored weekly using IVIS imaging. The luciferase counts for each animal during the in-life period (Days 0-25) are presented in Table 13 and plotted in Figure 6; IVIS images are presented in Figures 7-8. By the end of in-life period (Day 25) the tumors of TXR-311-treated animals were 3-fold smaller compared to vehicle-treated animals. This inhibition in tumor growth was statistically significant when compared to vehicle- treated animals (p ≤ 0.001, 2-way ANOVA). [122] Body weight data are provided in Table 12 and plotted in Figure 5. Animals bearing the PDX1 tumor which were treated with vehicle or 20 mg/kg of TXR-311 exhibited a decrease in body weight during the in-life period. By Day 21 animals treated with vehicle showed a 26% body weight loss and animals treated with TXR-311 showed a 18% body weight loss when compared to the average body weight at Day 0. Statistical analysis (2-way ANOVA) indicated that the difference in body weight change between treatment groups was not significant (p > 0.05). Due to the severe decrease in body weight along with large tumor dimensions, all mice were sacrificed on Day 25. Table 12. PDX1 - Body Weight
Table 13. PDX1 - Tumor Growth and Luciferase Counts
[123] PDX2 study: Tumor size was monitored weekly using IVIS. The luciferase counts for each animal during the in-life period (Days 0-42) is presented in Table 15 and plotted in Figure 12; IVIS images are presented in Figures 13-22. By the end of in-life period (Day 42) animals treated with TXR-311 or sorafenib had tumors that were 4 times smaller compared to vehicle- treated animals. This inhibition in tumor growth was statistically significant when compared to vehicle treated animals (p ≤ 0.001, 2-way ANOVA). A significant inhibition in tumor growth (p ≤ 0.05) was also observed on Day 35 in animals treated with TXR-311 but not in animals treated with sorafenib, the standard of care for HCC. [124] Body weight data are provided in Table 14 and plotted in Figure 11. Animals bearing PDX2 tumors that were treated with vehicle, 20 mg/kg TXR-311 or 50 mg/kg sorafenib showed a small increase (2-5%) in body weight. These results indicate that the severe body weight loss observed in the PDX1 study was the result of tumor growth and not due to TXR-311 toxicity. Table 14. PDX2 - Body Weight
Table 15. PDX2 - Tumor Growth and Luciferase Counts
* This animal was treated as an outlier as noted below. Tumor Volume. Animals in the PDX1 and PDX2 studies were sacrificed on Days 25 and 42 respectively. During necropsy, the liver was removed, the xenograft was excised and the tumor diameters (small (S) and large (L)) were measured. Tumor volume was calculated using the following formula: V= π/6 * L*S2. Tumor volume is presented in Tables 16 and 17 and plotted in Figures 10 and 24, tumor images are presented in Figures 9 and 23. Table 16. Tumor Measurements and Volume
Table 17. Tumor Measurements and Volume
*Identified as outlier and removed from the inferential statistics analysis [125] At termination of the in-life phase of the PDX1 study, animals treated with TXR-311 exhibit a mean tumor volume of 805 ± 187 mm3 while animals treated with vehicle show a larger mean tumor volume of 1876 ± 218 mm3. Statistical analysis indicated that this decrease was statistically significant (p ≤ 0.01, 2-way ANOVA). [126] At termination of the in-life phase of the PDX2 study, animals treated with TXR-311 had the lowest tumor volume when compared to vehicle- and sorafenib-treated animals: 750 ± 410 mm3 vs 2193 ± 688 mm3, and 1082 ± 485 mm3, respectively. Statistical analysis (non-parametric, one-way ANOVA) following a single outlier identification and removal indicated that these differences were statistically significant at p ≤ 0.05 only when comparing TXR-311 to vehicle- treated animals. Statistical analysis without the removal of the outlier indicated that these differences did not reach a statistical significance of p < 0.05 (p = 0.06). Five out of seven mice treated with TXR-311 had significantly reduced tumor volume compared to vehicle-treated animals. [127] Treating tumor-bearing mice with 20 mg/kg of TXR-311 significantly inhibited the growth of the two orthotopic HCC xenografts when compared to vehicle-treated animals. Measuring the tumor volume at the time of necropsy showed a significant decrease in PDX1 but
not in PDX2 xenograft when compared to vehicle-treated animals. Based on luciferase counts of in-life xenografts, TXR-311 reduced PDX1 and PDX2 tumor volume by 3- and 4-fold, respectively at the end of the treatment period. [128] In summary, preclinical cytotoxicity studies and patient derived xenograft animal model studies of TXR-311 suggest that certain CBS microtubule destabilizing agents constitute a class of drug candidates for the treatment of liver cancers such as HCC and possesses specificity for tumorigenic cells relative to normal hepatocytes. [129] All patent filings, websites, other publications, accession numbers and the like cited above or below are incorporated by reference in their entirety for all purposes to the same extent as if each individual item were specifically and individually indicated to be so incorporated by reference. Any feature, step, element, embodiment, or aspect of the disclosure can be used in combination with any other unless specifically indicated otherwise. Although the disclosure provides description, illustration, and examples for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.
Claims
WHAT IS CLAIMED IS: 1. A method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (I):
or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: R1 is H, C1-4 alkyl; Q is a bond, or C1-4 alkyl; A is aryl, heteroaryl optionally substituted with 0-3 substituents independently chosen from halogen, C1-4 alkyl, CH2F, CHF2, CF3, CN, aryl, hetaryl, OCF3, OC1-4alkyl, OC2- 5alkylNR4R5, Oaryl, Ohetaryl, CO2R4, CONR4R5, nitro, NR4R5, C1-4 alkylNR4R5, NR6C1- 4alkylNR4R5, NR4COR5, NR6CONR4R5, NR4SO2R5; R4, R5 are each independently H, C1-4 alkyl, C1-4 alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, aryl, hetaryl, C1-4alkyl aryl, C1-4 alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR7; R6 is selected from H, C1-4 alkyl; R7 is selected from H, C1-4 alkyl, aryl, hetaryl, C1-4alkyl aryl, C1-4 alkyl hetaryl; R2 is 0-2 substituents independently selected from halogen, C1-4alkyl, OH, OC1-4alkyl, CH2F, CHF2, CF3, OCF3, CN, C1-4alkylNR8R9, OC1-4alkylNR8R9, CO2R8, CONR8R9, NR8R9, NR8COR9, NR10CONR8R9, NR8SO2R9; R8, R9 are each independently H, C1-4 alkyl, C1-4 alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, aryl, hetaryl, C1-4 alkyl aryl, C1-4 alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR11;
R10 is selected from H, C1-4 alkyl, aryl or hetaryl; R11 is selected from H, C1-4 alkyl, aryl, hetaryl, C1-4alkyl aryl, C1-4 alkyl hetaryl; Y is halogen, OH, NR12R13, NR14COR12, NR14CONR12R13, N14SO2R13; R12 and R13 are each independently H, CH2F, CHF2, CF3, CN, C1-4 alkyl optionally substituted with OH, OC1-4alkyl or NR15 R16 , cycloalkyl; cyclohetalkyl, C1-4 alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, or may be joined to form an optionally substituted 3-6 membered ring optionally containing an atom selected from O, S, NR14; R14, R15 and R16 are each independently selected from H, C1-4 alkyl; n=0-4; W is selected from H, C1-4alkyl, C2-6alkenyl; where C1-4alkyl or C2-6alkenyl may be optionally substituted with C1-4alkyl, OH, OC1-4alkyl, NR15R16; R15, and R16 are each independently H, C1-4 alkyl, C1-4alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR17; and R17 is selected from H, C1-4 alkyl.
2. A method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (II):
or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: R1 is H, C1-4 alkyl; Q is a bond, or C1-4 alkyl;
A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C1-4 alkyl, CH2F, CHF2, CF3, CN, aryl, hetaryl, OCF3, OC1-4alkyl, OC2- 5alkylNR4R5, Oaryl, Ohetaryl, CO2R4, CONR4R5, nitro, NR4R5, C1-4 alkylN R4R5, NR6C1-4alkylN R4R5, NR4COR5, NR6CON R4R5, NR4SO2R5; R4, R5 are each independently H, C1-4 alkyl, C1-4 alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, aryl, hetaryl, C1-4alkyl aryl, C1-4 alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR7; R6 is selected from H, C1-4 alkyl; R7 is selected from H, C1-4 alkyl, aryl, hetaryl, C1-4alkyl aryl, C1-4 alkyl hetaryl; R2 is 0-2 substituents independently selected from C1-4alkyl and OC1-4alkyl; Y is CH2OH, OC1-4alkylOH, OC1-4alkylR12, OC1-4alkylNR12NR13, C(O)R12 , CH2R12, COOR12, CONR12R13, OCON R12R13, CH2N R12R13, NHCOR12, NHCON R12R13, R12 and R13 are each independently H, C1-2 alkyl, (CH2)3NEt2, (CH2)2NMe2, (CH2)5NH2, (CH2)2OH,
n=0-4; W is selected from H, C1-4alkyl, C2-6alkenyl; where C1-4alkyl or C2-6alkenyl may be optionally substituted with C1-4alkyl, OH, OC1-4alkyl, NR15R16; R15, and R16 are each independently H, C1-4 alkyl, C1-4alkyl cycloalkyl, C1-4 alkyl cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR17
R17 is selected from H, C1-4 alkyl; and wherein when Y is CH2R12 then R12 is not H, C1-2alkyl.
3. A method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (III):
or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: X1, X2, X3, X4 are selected from the following: (i) X1 and X2 are N and X3 and X4 are C independently substituted with Y; (ii) X1 and X4 are N and X2 and X3 are C independently substituted with Y; (iii) X1 and X3 are N and X2 and X4 are C independently substituted with Y; (iv) X2 and X4 are N and X1 and X3 are C independently substituted with Y; (v) X1 is N and X2, X3, and X4 are C independently substituted with Y; (vi) X3 is N and X1, X2, and X4 are C independently substituted with Y; (vii) X4 is N and X1, X2, and X3 are C independently substituted with Y; (viii) X2 is N and X1, X3, and X4 are C independently substituted with Y; and (ix) X1, X2 and X3 are N and X4 is C substituted with Y; R1 is H, C1-6alkyl, C1-6alkylNR5R6, C1-6alkylNR5COR6, C1-6alkylNR5SO2R6, C1-6alkylCO2R5, C1-6alkylCONR5R6; R5 and R6 are each independently H, C1-4alkyl, aryl, hetaryl, C1-4alkylaryl, C1- 4alkylhetaryl or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR7; R7 is selected from H, C1-4alkyl;
R2 is selected from C1-6alkylOH, OC2-6alkylOH, C1-6alkylNR8R9, OC2-6alkylN R8R9, C1- 6alkylNR8COR9, OC2-6alkylNR8COR9, C1-6alkylhetaryl, OC2-6alkylhetaryl, OCON R8R9, NR8COOR9, NR10CONR8R9, CONR8R9, NR8COR12; R8, R9 are each independently H, C1-4alkyl, C1-4alkylNR11R13, hetaryl, cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR14; R12 is C2-4alkyl, C1-4alkylNR11R13, hetaryl, cyclohetalkyl; R11, R13 are each independently H, C1-4alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR14; R14 is selected from H, C1-4alkyl; R10 is H, C1-4 alkyl; R3 and R4 are each independently H, halogen, C1-4alkyl, OH, OC1-4alkyl, CF3, OCF3; Q is a bond, or C1-4 alkyl; W is selected from H, C1-4alkyl, C2-6alkenyl; where C1-4alkyl or C2-6alkenyl may be optionally substituted with C1-4alkyl, OH, OC1-4alkyl, NR15R16; R15 and R16 are each independently H, C1-
alkyl, C1-4alkyl cycloalkyl, C1-4alkyl cyclohetalkyl, aryl, hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR17; R17 is selected from H, C1-4alkyl; A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C1-4 alkyl, CF3, aryl, hetaryl, OCF3, OC1-4alkyl, OC2-5alkylNR18R19, Oaryl, Ohetaryl, CO2R18, CONR18R19, NR18R19, C1-4 alkylNR18R19, NR20C1-4alkylNR18R19, NR18COR19, NR20CONR18R19, NR18 SO2R19; R18, R19 are each independently H, C1-4 alkyl, C1-4 alkyl cyclohetalkyl, aryl, hetaryl, C1- 4alkyl aryl, C1-4 alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21; R21 is selected from H, C1-4alkyl; R20 is selected from H, C1-4alkyl; Y is selected from H, C1-4alkyl, OH, NR22R23; and R22, R23 are each independently H, C1-4alkyl.
4. A method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (IV):
or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: X1, X2, X3, X4 are selected from the following: (i) X1 and X2 are N and X3 and X4 are C independently substituted with Y; (ii) X1 and X4 are N and X2 and X3 are C independently substituted with Y; (iii) X1 and X3 are N and X2 and X4 are C independently substituted with Y; (iv) X2 and X4 are N and X1 and X3 are C independently substituted with Y; (v) X1 is N and X2, X3, and X4 are C independently substituted with Y; (vi) X3 is N and X1, X2, and X4 are C independently substituted with Y; (vii) X4 is N and X1, X2, and X3 are C independently substituted with Y; (viii) X2 is N and X1, X3, and X4 are C independently substituted with Y; and (ix) X1, X2 and X3 are N and X4 is C substituted with Y; R1 is H, C1-6alkyl, C1-6alkylNR5R6, where R5 and R6 are each independently H, C1-4alkyl, aryl, hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR7; R7 is selected from H, C1-4alkyl; R2 is selected from C1-6alkylOH, OC2-6alkyl OH, C1-6alkylNR8R9, OC2-6alkyl NR8R9, C1- 6alkylNR8COR9, OC2-6alkylNR8COR9, C1-6alkylhetaryl, OC2-6alkylhetaryl, OCONR8R9, NR8COOR9, NR10CONR8R9, CONR8R9, NR8COR12; R8, R9 are each independently H, C1-4alkyl, C1-4alkylNR11R13, hetaryl, cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR14;
R12 is C2-4alkyl, C1-4alkylNR11R13, hetaryl, cyclohetalkyl; R11, R13 are each independently H, C1-4alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR14; R14 is selected from H, C1-4alkyl; R10 is H, C1-4alkyl; R3 and R4 are each independently H, halogen, C1-4alkyl, OH, OC1-4alkyl, CF3, OCF3; Q is CH; W is selected from C1-4alkyl, C2-6alkenyl; where C1-4alkyl or C2-6alkenyl may be optionally substituted with C1-4alkyl, OH, OC1-4alkyl, NR15R16; R15, and R16 are each independently H, C1-4alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR17; R17 is selected from H, C1-4alkyl; A is aryl, hetaryl optionally substituted with 0-2 substituents independently chosen from halogen, C1-4alkyl, CF3, aryl, hetaryl, OCF3, OC1-4alkyl; OC2-3alkylNR18R19, Oaryl, Ohetaryl, CO2R18, CONR18R19, NR18R19, C1-4alkylNR18R19, NR20C1-4alkylNR18R19, NR18COR19, NR20CONR18R19, NR18SO2R19; R18, R19 are each independently H, C1-4alkyl, C1-4alkyl cyclohetalkyl, aryl, hetaryl, C1- 4alkyl aryl, C1-4alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21; R21 is selected from H, C1-4alkyl; R20 is selected from H, C1-4alkyl; Y is selected from H, C1-4alkyl, NR22R23; and R22, R23 are each independently H, C1-4alkyl.
5. A method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (V):
or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: X1, X2, X3, X4 are selected from the following: (i) X1 and X2 are N and X3 and X4 are C independently substituted with Y; (ii) X1 and X4 are N and X2 and X3 are C independently substituted with Y; (iii) X2 and X4 are N and X1 and X3 are C independently substituted with Y; (iv) X1 is N and X2, X3, and X4 are C independently substituted with Y; (v) X3 is N and X1, X2, and X4 are C independently substituted with Y; (vi) X4 is N and X1, X2, and X3 are C independently substituted with Y; (vii) X2 is N and X1, X3, and X4 are C independently substituted with Y; and (viii) X1, X2 and X3 are N and X4 is C substituted with Y; R1 is H, C1-6alkyl, C1-6 alkylNR5R6, C1-6alkylNR5COR6, C1-6alkylNR5SO2R6, C1-6alkylCO2R5, C1-6alkylCONR5R6; R5 and R6 are each independently H, C1-4alkyl, aryl, hetaryl, C1-4alkylaryl, C1- 4alkylhetaryl or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR7; R7 is selected from H, C1-4alkyl; R2 is selected from OH, OC1-6alkyl, C1-6alkylOH, OC2-6alkylOH, C1-6alkylNR8R9, OC2- 6alkylNR8R9, C1-6alkylNR8COR9, OC2-6alkylNR8COR9, C1-6alkylhetaryl, OC2- 6alkylhetaryl, OCONR8R9, NR8COOR9, NR10CONR8R9, CONR8R9, NR8COR12; R8, R9 are each independently H, C1-4alkyl, C1-4alkylNR11R13, hetaryl, cyclohetalkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR14; R12 is C2-4alkyl, C1-4alkylNR11R13, hetaryl, cyclohetalkyl;
R11, R13 are each independently H, C1-4alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR14; R14 is selected from H, C1-4alkyl; R10 is H, C1-4 alkyl; R3 and R4 are each independently H, halogen, C1-4alkyl, OH, OC1-4alkyl, CF3, OCF3; Q is a bond, or C1-4alkyl; W is selected from H, C1-4alkyl, C2-6alkenyl; where C1-4alkyl or C2-6alkenyl may be optionally substituted with C1-4alkyl, OH, OC1-4alkyl, NR15R16; R15, and R16 are each independently H, C1-4alkyl, C1-4alkyl cycloalkyl, C1-4alkyl cyclohetalkyl, aryl, hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR17; R17 is selected from H, C1-4alkyl; A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C1-4 alkyl, CF3, aryl, hetaryl, OCF3, OC1-4alkyl, OC2-5alkylNR18R19, Oaryl, Ohetaryl, CO2R18, CONR18R19, NR18R19, C1-4 alkylNR18R19, NR20C1-4alkylNR18R19, NR18COR19, NR20CONR18R19, NR18SO2R19; R18, R19 are each independently H, C1-4 alkyl, C1-4 alkyl cyclohetalkyl, aryl, hetaryl, C1- 4alkyl aryl, C1-4 alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21; R21 is selected from H, C1-4 alkyl; R20 is selected from H, C1-4 alkyl; Y is selected from H, C1-4alkyl, OH, NR22R23; R22, R23 are each independently H, C1-4 alkyl.
6. A method of treating liver cancer comprising administering to a subject in need of treatment an amount of at least one compound of the general formula (VI):
or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein: R’1 is C1-4 alkyl, R’2 is independently selected from the group consisting of: OH, NHCOR’12, and NHCONHR’12; R’12 is independently selected from the group consisting of H, C1-4 alkyl optionally substituted with OH, OC1-4alkyl or NR’15R’16; R’15 and R’16 are each independently selected from H and C1-4 alkyl; X’1, X’2, X’3, X’4 are selected from the following: (i) X’1 and X’2 are N and X’3 and X’4 are C independently substituted with Y’; (ii) X’1 and X’4 are N and X’2 and X’3 are C independently substituted with Y’; (iii) X’1 and X’3 are N and X’2 and X’4 are C independently substituted with Y’; (iv) X’2 and X’4 are N and X’1 and X’3 are C independently substituted with Y’; Y’ is selected from H, OH, C1-4alkyl, and OC1-4alkyl; X’5 is selected from N and C, and when X’5 is C, R’6 is selected from the group H, halogen, C1-4 alkyl, OC1-4alkyl, CF3, and OCF3: R’5 is selected from the group C1-4 alkyl, OC1-4alkyl, CF3, and OCF3; and R’7 is selected from the group H, halogen, C1-4 alkyl, OC1-4alkyl, CF3, and OCF3. 7. The method according to claim 6, wherein the compound of the general formula (VI) selected from the group consisting of:
or a pharmaceutically acceptable prodrug, salt, hydrate, solvate, or crystal form thereof. 8. The method of claim 7, wherein the compound is
or a pharmaceutically acceptable prodrug, salt, hydrate, solvate, or crystal form thereof. 9. The method of any of claims 1-8, wherein the liver cancer is selected from the group consisting of: hepatocellular carcinoma (HCC), fibrolamellar HCC, bile duct cancer, angiosarcoma, and secondary liver cancer. 10. The method of any of claims 1-8, wherein the liver cancer is HCC. 11. The method of any of claims 1-10, wherein the subject is a human. 12. The method of any of claims 1-10, further comprising monitoring the subject for change(s) in sign(s) and/or symptom(s) of liver cancer responsive to administering the compound. 13. The method of any of claims 1-10, wherein the compound is administered as a monotherapy. 14. The method of any of claims 1-10, further comprising administering a second therapeutic agent to the subject. 15. The method of any of claims 1-10, wherein the compound is administered intravenously, subcutaneously, or orally. 16. Use of a compound of the general formulas (I), (II), (III), (IV), (V), or (VI) for the treatment of liver cancer. 17. The use according to claim 16, wherein the compound is selected from
or a pharmaceutically acceptable prodrug, salt, hydrate, solvate, or crystal form thereof. 18. The use according to claim 17, wherein the compound is
or a pharmaceutically acceptable prodrug, salt, hydrate, solvate, or crystal form thereof. 19. The use according to any of claims 16-18, wherein the liver cancer is selected from the group consisting of: hepatocellular carcinoma (HCC), fibrolamellar HCC, bile duct cancer, angiosarcoma, and secondary liver cancer. 20. The use according to any of claims 16-18, wherein the liver cancer is HCC. 21. The use according to any of claims 16-20, wherein the treatment is applied to a human.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063110148P | 2020-11-05 | 2020-11-05 | |
US63/110,148 | 2020-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022098808A1 true WO2022098808A1 (en) | 2022-05-12 |
Family
ID=81457454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/057970 WO2022098808A1 (en) | 2020-11-05 | 2021-11-04 | Therapeutic agents for treating hepatocellular carcinoma |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022098808A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080015191A1 (en) * | 2004-12-22 | 2008-01-17 | The Wellcome Trust Limited | Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds |
-
2021
- 2021-11-04 WO PCT/US2021/057970 patent/WO2022098808A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080015191A1 (en) * | 2004-12-22 | 2008-01-17 | The Wellcome Trust Limited | Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds |
Non-Patent Citations (1)
Title |
---|
DATABASE PubChem substance ANONYMOUS : "SID 391291015 ", XP055937869, retrieved from NCBI Database accession no. 391291015 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9889137B2 (en) | Therapeutically active compounds and their methods of use | |
CN105008343B (en) | Alternatively benzothiophene derivative of property ERs degradation agent and combinations thereof | |
EP3672591B1 (en) | Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/or bendamustine or bcl-2 inhibitor combined with chop | |
TW201601727A (en) | Methods for the treatment of solid tumors | |
JP2009538317A (en) | Drug combinations using substituted diarylureas for cancer treatment | |
CN110461853A (en) | Benzothiophene estrogenic agents | |
CN104487089A (en) | Combination therapy of a mek inhibitor and igf1r inhibitor | |
WO2012000421A1 (en) | Uses of gossypol derivatives in manufacture of antitumor medicaments | |
KR20210038906A (en) | Methods of treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use therein | |
EP3296294B1 (en) | Compound for treating or preventing breast cancer | |
JP7234418B2 (en) | BRAFV600E triple combination of ERK1/2 inhibitor with BRAF inhibitor and EGFR inhibitor for use in treating colon cancer | |
WO2020192506A1 (en) | Chiauranib for treatment of small cell lung cancer | |
CN100467450C (en) | Anthranilic acid amides and pharmaceutical use thereof | |
CA3017557A1 (en) | Combination therapy for proliferative diseases | |
WO2023107861A1 (en) | Aminopyrazole derivatives as cdk7 inhibitors for use in treating in cancer | |
WO2022098808A1 (en) | Therapeutic agents for treating hepatocellular carcinoma | |
JP6179904B2 (en) | Side effects of sorafenib | |
US20230390277A1 (en) | Methods to sensitize tumors to treatment by immunotherapy | |
TW201602086A (en) | Arylamine substututed quinoxaline and their use as anticancer drugs | |
JP2019014685A (en) | Anticancer agent | |
JP2020023447A (en) | Phenyl tetrahydropyridoindol derivative and pharmaceutical composition | |
CN111821303B (en) | Application of vortioxetine and salts thereof in preparation of antitumor drugs | |
TW201406759A (en) | Use of VEGFR-3 inhibitors for treating hepatocellular carcinoma | |
JP6152387B2 (en) | Treatment of type I and type II diabetes | |
CN111170962A (en) | Application of 4- (benzoselenazole-2-yl) arylamine compound in treating intestinal cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21890023 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21890023 Country of ref document: EP Kind code of ref document: A1 |